Document/ExhibitDescriptionPagesSize 1: 10-Q Quarterly Report HTML 977K
2: EX-10.1 Material Contract HTML 100K
3: EX-10.2 Material Contract HTML 100K
4: EX-10.3 Material Contract HTML 144K
5: EX-10.4 Material Contract HTML 103K
6: EX-10.5 Material Contract HTML 154K
7: EX-10.6 Material Contract HTML 156K
8: EX-10.7 Material Contract HTML 157K
9: EX-10.8 Material Contract HTML 154K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 32K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 32K
19: R1 Cover Page HTML 90K
20: R2 Consolidated Balance Sheets HTML 158K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
22: R4 Consolidated Statements of Operations HTML 116K
23: R5 Consolidated Statements of Changes in HTML 92K
Stockholders' / Members? Equity
24: R6 Consolidated Statements of Cash Flows HTML 140K
25: R7 Nature of Operations HTML 39K
26: R8 Significant Accounting Policies HTML 63K
27: R9 The COVID-19 Pandemic HTML 37K
28: R10 Business Combinations HTML 49K
29: R11 Variable Interest Entities HTML 58K
30: R12 Revenue Recognition HTML 120K
31: R13 Property and Equipment HTML 44K
32: R14 Leases HTML 71K
33: R15 Intangible Assets HTML 57K
34: R16 Goodwill HTML 40K
35: R17 Accounts Payable and Accrued Expenses HTML 41K
36: R18 Long-Term Debt HTML 51K
37: R19 Fair Value Measurements HTML 104K
38: R20 Shareholders' Equity HTML 46K
39: R21 Noncontrolling Interest HTML 38K
40: R22 Equity-Based Compensation HTML 62K
41: R23 Loss Per Share HTML 52K
42: R24 Transaction-related Expenses HTML 33K
43: R25 Commitment and Contingencies HTML 58K
44: R26 Income Taxes HTML 40K
45: R27 Segment Reporting HTML 66K
46: R28 Concentrations HTML 40K
47: R29 Related Party Transactions HTML 36K
48: R30 Subsequent Events HTML 33K
49: R31 Significant Accounting Policies (Policies) HTML 85K
50: R32 Significant Accounting Policies (Tables) HTML 46K
51: R33 Business Combinations (Tables) HTML 43K
52: R34 Variable Interest Entities (Tables) HTML 56K
53: R35 Revenue Recognition (Tables) HTML 113K
54: R36 Property and Equipment (Tables) HTML 43K
55: R37 Leases (Tables) HTML 73K
56: R38 Intangible Assets (Tables) HTML 57K
57: R39 Goodwill (Tables) HTML 40K
58: R40 Accounts Payable and Accrued Expenses (Tables) HTML 41K
59: R41 Long-Term Debt (Tables) HTML 53K
60: R42 Fair Value Measurements (Tables) HTML 107K
61: R43 Noncontrolling Interest (Tables) HTML 37K
62: R44 Equity-Based Compensation (Tables) HTML 56K
63: R45 Loss Per Share (Tables) HTML 52K
64: R46 Commitment and Contingencies (Tables) HTML 46K
65: R47 Segment Reporting (Tables) HTML 60K
66: R48 Concentrations (Tables) HTML 39K
67: R49 Nature of Operations (Details) HTML 54K
68: R50 Significant Accounting Policies - Narrative HTML 54K
(Details)
69: R51 Significant Accounting Policies - Cash, Cash HTML 41K
Equivalents and Restricted Cash (Details)
70: R52 Business Combinations - Narrative (Details) HTML 70K
71: R53 Business Combinations - Schedule of Preliminary HTML 72K
Fair Value of Net Assets Acquired (Details)
72: R54 Variable Interest Entities - Narrative (Details) HTML 68K
73: R55 Variable Interest Entities - Schedule of Variable HTML 101K
Interest Entities (Details)
74: R56 Revenue Recognition - Narrative (Details) HTML 33K
75: R57 Revenue Recognition - Disaggregation of Revenue HTML 48K
(Details)
76: R58 Revenue Recognition - Schedule of Related Balance HTML 65K
Sheets Account (Details)
77: R59 Revenue Recognition - Contract Assets (Details) HTML 39K
78: R60 Revenue Recognition - Contract Liabilities HTML 39K
(Details)
79: R61 Revenue Recognition - Deferred Revenue (Details) HTML 39K
80: R62 Revenue Recognition - Shared Savings Payable HTML 36K
(Details)
81: R63 Property and Equipment - Property and Equipment, HTML 50K
net (Details)
82: R64 Property and Equipment - Narrative (Details) HTML 35K
83: R65 Leases - Narrative (Details) HTML 71K
84: R66 Leases - Summary of Impact of ASC 842 Adoption HTML 53K
(Details)
85: R67 Leases - Operating Lease Right-of-Use Assets and HTML 39K
Lease Liabilities (Details)
86: R68 Leases - Components of Lease Expense (Details) HTML 39K
87: R69 Leases - Weighted Average Remaining Lease Term and HTML 35K
Discount Rate of Operating Leases (Details)
88: R70 Leases - Schedule of Maturities of Operating Lease HTML 50K
Liabilities (Details)
89: R71 Leases - Schedule of Future Minimum Lease Payments HTML 48K
(Details)
90: R72 Intangible Assets - Schedule of Intangible Assets HTML 55K
(Details)
91: R73 Intangible Assets - Narrative (Details) HTML 56K
92: R74 Intangible Assets - Schedule of Expected HTML 46K
Amortization Expense (Details)
93: R75 Goodwill - Change in Carrying Amount of Goodwill HTML 41K
(Details)
94: R76 Goodwill - Narrative (Details) HTML 33K
95: R77 Accounts Payable and Accrued Expenses (Details) HTML 46K
96: R78 Long-Term Debt - Schedule of Long-Term Debt HTML 55K
(Details)
97: R79 Long-Term Debt - Narrative (Details) HTML 50K
98: R80 Long-Term Debt - Future Principal Maturities of HTML 49K
Long-Term Debt (Details)
99: R81 Fair Value Measurements - Schedule of Assets and HTML 60K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
100: R82 Fair Value Measurements - Changes in Contingent HTML 58K
Consideration and Customer Equity Appreciation
Rights (Details)
101: R83 Fair Value Measurements - Schedule of Valuation HTML 86K
Techniques and Significant Unobservable Inputs
(Details)
102: R84 Shareholders' Equity (Details) HTML 64K
103: R85 Noncontrolling Interest - Summary of Ownership HTML 46K
Interests in Cure TopCo (Details)
104: R86 Noncontrolling Interest - Narrative (Details) HTML 40K
105: R87 Equity-Based Compensation - Narrative (Details) HTML 101K
106: R88 Equity-Based Compensation - Schedule of Stock HTML 62K
Options Activity (Details)
107: R89 Equity-Based Compensation - Schedule of Restricted HTML 57K
Stock Units Activity (Details)
108: R90 Loss Per Share - Schedule of Earnings (Loss) Per HTML 74K
Share (Details)
109: R91 Loss Per Share - Narrative (Details) HTML 36K
110: R92 Loss Per Share - Anti-Dilutive Shares (Details) HTML 40K
111: R93 Transaction-related Expenses (Details) HTML 37K
112: R94 Commitment and Contingencies - Narrative (Details) HTML 73K
113: R95 Commitment and Contingencies - Summary of EAR HTML 46K
Letter Agreement (Details)
114: R96 Commitment and Contingencies - Summary of SEU HTML 43K
Activity (Details)
115: R97 Income Taxes (Details) HTML 48K
116: R98 Segment Reporting - Narrative (Details) HTML 32K
117: R99 Segment Reporting - Schedule of Operating Segment HTML 76K
Results (Details)
118: R100 Concentrations - Schedule of Customer HTML 42K
Concentration Risk (Details)
119: R101 Concentrations - Narrative (Details) HTML 45K
120: R102 Subsequent Events (Details) HTML 41K
121: R9999 Uncategorized Items - sgfy-20220331.htm HTML 130K
124: XML IDEA XML File -- Filing Summary XML 220K
122: XML XBRL Instance -- sgfy-20220331_htm XML 2.35M
123: EXCEL IDEA Workbook of Financial Reports XLSX 144K
15: EX-101.CAL XBRL Calculations -- sgfy-20220331_cal XML 261K
16: EX-101.DEF XBRL Definitions -- sgfy-20220331_def XML 1.05M
17: EX-101.LAB XBRL Labels -- sgfy-20220331_lab XML 2.09M
18: EX-101.PRE XBRL Presentations -- sgfy-20220331_pre XML 1.44M
14: EX-101.SCH XBRL Schema -- sgfy-20220331 XSD 252K
125: JSON XBRL Instance as JSON Data -- MetaLinks 507± 742K
126: ZIP XBRL Zipped Folder -- 0001828182-22-000029-xbrl Zip 564K
(Registrant’s
telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on
which registered
iClass A common stock, par value $0.01 per Share
iSGFY
iNew
York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
iYes
☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
iYes
☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated
filer
☐
iNon-accelerated filer
☒
Smaller reporting company
i☐
Emerging growth company
i☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Yes ☐ No i☒
Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes i☐ No ☒
As of April 30, 2022, there were i176,317,381
outstanding shares of Class A common stock, $0.01 par value, and i57,372,117 outstanding shares of Class B common stock, $0.01 par value.
Class A common stock, par value $ii0.01/
(ii176,232,513/ and ii170,987,365/
issued and outstanding at March 31, 2022 and December 31, 2021, respectively)
i1.8
i1.7
Class
B common stock, par value $ii0.01/ (ii57,313,051/
and ii56,838,744/ issued and outstanding at March
31, 2022 and December 31, 2021, respectively)
i0.6
i0.6
Additional
paid-in capital
i1,160.0
i1,101.3
Retained
earnings
i8.4
i19.7
Contingently redeemable
noncontrolling interest
i375.1
i369.6
Total stockholders' equity
i1,545.9
i1492.9
Total
liabilities and stockholders' equity
$
i2,271.4
$
i2,127.2
See
accompanying notes to the condensed consolidated financial statements.
Notes to the Condensed Consolidated Financial Statements (unaudited)
1.iNature
of Operations
Signify Health, Inc. (referred to herein as “we”, “our”, “us”, “Signify Health” or the “Company”) was incorporated in the state of Delaware on October 1, 2020 and was formed for the purpose of completing an initial public offering (“IPO”) of its common stock and related reorganization transactions as described below. As a result of the reorganization transactions in February 2021, we control, and therefore consolidate the operations of Cure TopCo, LLC (“Cure TopCo”) and its direct and indirect subsidiaries.
Cure TopCo is a Delaware limited liability company formed on November
3, 2017. Cure TopCo has adopted a holding company structure and is the indirect parent company of Signify Health, LLC (“Signify”), a Delaware limited liability company. Signify was formed on November 3, 2017. Operations are performed through our wholly-owned subsidiaries.
We are a healthcare platform that leverages advanced analytics, technology and nationwide healthcare provider networks to create and power value-based payment programs. Our customers include health plans, governments, employers, health systems and physician groups. We operate in itwo
segments of the value-based healthcare payment industry: payment models based on individual episodes of care, or the Episodes of Care Services segment, and in-home health evaluations (“IHE”), or the Home & Community Services segment. Payment models based on individual episodes of care organize or bundle payments for all, or a substantial portion of, services received by a patient in connection with an episode of care, such as a surgical procedure, particular condition or other reason for a hospital stay. IHEs are health evaluations performed by a clinician in the home to support payors’ participation in Medicare Advantage and other government-run managed care plans. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, care coordination and cost-savings.
Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home.
On March 1, 2022, we acquired Caravan Health, Inc. (“Caravan Health”), see Note 4. Business Combinations. With this combination, we will now be able to provide a broader range of value-based and shared savings models from advanced primary care to specialty care bundles to total cost of care programs.
Initial Public Offering
On February
16, 2021, we closed an initial public offering (“IPO”) of i27,025,000 shares of our Class A common stock at a public offering price of $i24 per
share, which included i3,525,000 shares issued pursuant to the full exercise of the underwriters’ over-allotment option. We received gross proceeds of $i648.6 million,
which resulted in net cash proceeds of $i609.7 million after deducting underwriting discounts and commissions of $i38.9 million and before fees and expenses incurred in connection with the IPO
and paid for by Cure TopCo. We used the proceeds to purchase newly-issued membership interests from Cure TopCo at a price per interest equal to the IPO price of our Class A common stock, net of the underwriting discount and commissions.
Reorganization Transactions
In connection with the IPO, Signify Health and Cure TopCo completed a series of transactions (“Reorganization Transactions”), the effects of which included, among other things, Signify Health becoming the controlling shareholder of Cure TopCo.
As of March 31, 2022, we owned approximately i75.5%
of the economic interest in Cure TopCo. The non-controlling interest, consisting of certain pre-IPO members who retained their equity ownership in Cure TopCo subsequent to the Reorganization Transactions owned the remaining i24.5% economic interest in Cure TopCo.
Notes to the Condensed Consolidated Financial Statements (unaudited)
2.iSignificant Accounting Policies
i
Basis
of Presentation
These Condensed Consolidated Financial Statements are unaudited and have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and following the rules and regulations of the Securities and Exchange Commission (the “SEC”). The financial statements included in this report should be read in conjunction with the Company’s audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. In our opinion, they reflect all adjustments, including normal recurring items, that are necessary to present fairly the results of interim periods. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with
GAAP have been condensed or omitted as permitted by such rules and regulations; however, we believe that the disclosures are adequate to make the information presented not misleading. Operating results for the periods presented herein are not necessarily indicative of the results that may be expected for future interim periods or the entire fiscal year. Our quarterly results of operations, including our revenue, income from operations, net loss and cash flows, have varied and may vary significantly in the future, and period-to-period comparisons of our results of operations may not be meaningful. Accordingly, our interim results should not be relied upon as an indication of future performance.
i
For
the periods subsequent to the Reorganization Transactions effective February 12, 2021, the Condensed Consolidated Financial Statements represent Signify Health and our consolidated subsidiaries, including Cure TopCo. For the periods prior to the Reorganization Transactions, the condensed consolidated financial statements represent Cure TopCo and its consolidated subsidiaries, see Note 1 Nature of Operations. Signify Health was formed for the purpose of the IPO, which was effective in February 2021 and had no activities of its own prior to such date. We are a holding company and our sole material asset is a controlling ownership interest in Cure
TopCo.
The Condensed Consolidated Financial Statements include the accounts and financial statements of our wholly-owned subsidiaries and variable interest entities (“VIE”s) where we are the primary beneficiary. See Note 5 Variable Interest Entities. Results of operations of VIEs are included from the dates we became the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation.
We have itwo
operating segments, Home & Community Services and Episodes of Care Services as described in Note 1 Nature of Operations.
i
Use of Estimates
The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions affecting the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. These estimates are based on information available as of the date of the Condensed Consolidated Financial Statements;
therefore, actual results could differ from those estimates. The significant estimates underlying our Condensed Consolidated Financial Statements include revenue recognition; allowance for doubtful accounts; recoverability of long-lived assets, intangible assets and goodwill; loss contingencies; accounting for business combinations, including amounts assigned to definite and indefinite lived intangible assets and contingent consideration; customer equity appreciation rights; and equity-based compensation.
As of March 31, 2022, the COVID-19 pandemic continues to evolve and impact our Episodes of Care Services segment due to the passage of time between episode initiation and the performance and subsequent recognition of revenue for our services; See Note 3 The COVID-19
Pandemic. As a result, many of our estimates and assumptions have required increased judgment and carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.
i
Comprehensive Income (Loss)
We have not identified any incremental items that would be considered a component of comprehensive income (loss) and accordingly a statement of comprehensive income (loss) is
not reflected in the Condensed Consolidated Financial Statements because net loss and comprehensive loss are the same.
i
Restricted Cash
Under our Master Agreement with the Centers for Medicare and Medicaid Services (“CMS”), we were required to place certain funds in escrow for the benefit of CMS. These amounts, known as a Secondary Repayment Source
Notes to the Condensed Consolidated Financial Statements (unaudited)
(“SRS”), were primarily based on the size of our participation in the legacy CMS Bundled Payments for Care Improvement (“BPCI”) program, the predecessor program of the Bundled Payments for Care Improvement - Advanced initiative (“BPCI-A”). These funds were available to CMS as a supplemental payment source if we failed to pay amounts owed to CMS. Under the agreement, the funds are returned to us i18
months after the conclusion of the effective period of the CMS Master Agreement, or when all financial obligations to CMS are fulfilled. As of December 31, 2021, there was $i0.5 million in the SRS account included in restricted cash on the Condensed Consolidated Balance Sheets related to BPCI-A, all of which was released in the first quarter 2022.
We also withhold a portion of shared savings to customers in a “holding pool” to cover any potential subsequent negative
adjustments through CMS’s subsequent reconciliation true-up process. These funds are distributed to customers following the final true-up if there is no negative adjustment. These amounts represent consideration payable to the customer and therefore have reduced revenue in the period earned. The funds have been received by us from CMS and are held in a separate cash account, included as restricted cash on the Condensed Consolidated Balance Sheets. Since the funds are payable to the customer at the point the final CMS true-up is made or a negative adjustment is due to us, the amounts are also included in accounts payable and accrued expenses on the Condensed Consolidated Balance Sheets. As of March 31, 2022 and December 31, 2021, there was $i1.8
million and $i5.2 million of restricted cash in the holding pool, respectively.
In addition, as of March 31, 2022 we hold $i0.5 million
in a separate cash account, included as restricted cash on the Condensed Consolidated Balance Sheets, in relation to an accountable care organization (“ACO”) owned by Caravan Health. This ACO is part of a risk model under the CMS Medicare Shared Savings Program (“MSSP”) program where it shares in both the savings and losses. The ACO has a master letter of credit with CMS as the recipient where the letter of credit is used as protection against unpaid losses, should the ACO fail to remit payment in the event that losses occur. The letter of credit is collateralized by the ACO members, by either cash remitted or subordinated letters of credit. This restricted cash will only be used if an ACO member fails to remit payment in connection with a subordinated letter of credit.
ii
The
following table reconciles cash, cash equivalents, and restricted cash per the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets:
Accounts receivable primarily consist of amounts due from customers and CMS and are stated at their net realizable value. Management evaluates all accounts periodically and an allowance is established based on the latest information available to management. Management considers historical realization data, accounts receivable aging trends and other operational trends to estimate the collectability of receivables. After all reasonable attempts to collect a receivable have been exhausted, the receivable is written off against the allowance for doubtful accounts. As of March 31, 2022 and December 31, 2021, we had an allowance for doubtful accounts of $i9.7
million and $i7.9 million, respectively.
iAdvertising and Marketing Costs
Advertising
and marketing costs are included in selling, general and administrative expenses (“SG&A”) and are expensed as incurred. Advertising and marketing costs totaled $i0.2 million and $i0.3 million for the three months ended March
31, 2022 and 2021, respectively.
i
Accounting for Leases
We lease various property and equipment, with the majority of our leases consisting of real estate leases. Effective January 1, 2022, we adopted ASC Topic 842 Leases (“ASC 842”). Under ASC 842, a lease is a contract,
or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. Our contracts determined to be or contain a lease include explicitly or implicitly identified assets where we have the right to substantially all of the economic benefits of the assets and we have the
Notes to the Condensed Consolidated Financial Statements (unaudited)
ability
to direct how and for what purpose the assets are used during the lease term. Leases are classified as either operating or financing. All of our leases meet the criteria to be classified as operating leases. For operating leases, we recognize a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as prepaid rents, initial direct costs and lease incentives received from the lessor. We use the incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate is the rate of interest that we would have to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment.
Certain of our leases include variable lease costs to reimburse the lessor for real estate tax and
insurance expenses and certain non-lease components that transfer a distinct service to us, such as common area maintenance services. We have elected not to separate the accounting for lease components and non-lease components for all leased assets.
We sublease portions of our office space where we do not use the entire space for our operations. Sublease income is recorded as a reduction of lease expense.
i
Recent
Accounting Pronouncements
Recently Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842) which requires lessees to recognize leases on the balance sheet by recording a right-of-use asset and lease liability. This guidance is effective for non-public entities for annual reporting periods beginning after December 15, 2021. We adopted this new guidance as of January 1, 2022 and applied the transition option, whereby prior comparative periods will not be retrospectively presented in the consolidated financial statements. We elected the package of practical expedients not to reassess prior conclusions related
to contracts containing leases, lease classification and initial direct costs and the lessee practical expedient to combine lease and non-lease components for all asset classes. We made a policy election to not recognize right-of-use assets and lease liabilities for short-term leases for all asset classes.See Note 8 Leases.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts
with Customers (“ASU 2021-08”) which requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date of the amendments. We elected to early adopt this new guidance for interim periods in 2022 beginning with the Caravan Health acquisition on March 1, 2022. We measured the acquired contract
assets and liabilities in accordance with Topic 606. See Note 4 Business Combinations.
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (“ASU 2021-10”) which requires annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities for fiscal years beginning after December 31, 2021. We adopted this new guidance
as of January 1, 2022. There was no material impact on our condensed consolidated financial statements upon adoption.
Pending Adoption
We are an “emerging growth company” under the Jumpstart Our Business Startups Act (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. The effective dates below are the effective dates
we expect to adopt the new accounting pronouncements, which are those permitted for a company that is not an issuer.
Notes to the Condensed Consolidated Financial Statements (unaudited)
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses(Topic 326) (“ASU 2016-13”) which introduced the current expected credit losses methodology for estimating allowances for credit losses.
ASU 2016-13 applies to all financial instruments carried at amortized cost and off-balance-sheet credit exposures not accounted for as insurance, including loan commitments, standby letters of credit, and financial guarantees. The new accounting standard does not apply to trading assets, loans held for sale, financial assets for which the fair value option has been elected, or loans and receivables between entities under common control. ASU 2016-13 is effective for non-public entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We are evaluating the impact of this new guidance on our condensed consolidated financial statements.
3.iThe
COVID-19 Pandemic
Our operations in our Home & Community Services segment were significantly affected by the COVID-19 pandemic early in 2020. However, as the COVID-19 pandemic has evolved, we have been able to pivot and flex the volume of virtual IHEs (“vIHEs”) if needed and as a result we have not experienced a material impact to our results of operation in our Home & Community Services segment as a result of the ongoing pandemic since the second quarter of 2020.
Our Episodes of Care Services segment has experienced a prolonged negative impact related to the pandemic. At certain times during the pandemic, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments, including certain acute and post-acute care services,
be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with the COVID-19 virus. In addition, the temporary suspension or cancellation of services was put in place to focus limited resources and personnel capacity toward the prevention of, and care for patients with, COVID-19. This resulted in fewer elective procedures and a general reduction in individuals seeking medical care starting at the end of the first quarter of 2020, which contributed to a substantially lower number of episodes being managed in 2020 and 2021. Due to the nature of the BPCI-A program, however, there is a significant lag between when the episodes are initiated and when CMS reconciles those services and we recognize revenue over a 13 month period encompassing both of those points in time. As such, there was no immediate impact to our revenues in early 2020 when the pandemic began. However, the specific impact of the lower volumes on our program
size and revenues has resulted in a decline in weighted average program size and savings rates. In addition, in the third quarter of 2020 and in response to the COVID-19 pandemic, CMS announced that all episodes with a COVID-19 diagnosis irrespective of the impact on the outcome of the episode, would be excluded from reconciliation, and this exclusion has extended into 2022, resulting in a negative impact to our program size. We expect this impact on the program size to decrease once the COVID-19 pandemic subsides or CMS removes this rule.
Initially, the reduction in the number of episodes managed was offset by a higher savings rate achieved due to a combination of improved performance by some of our partners as well as certain partners that were underperforming choosing to exclude some or all of their episodes from reconciliation in 2020. However, beginning
with the reconciliation results received from CMS during the second quarter of 2021, we saw a negative impact on our savings rate as a result of the COVID-19 pandemic, primarily related to the under-diagnosis of co-morbidities and the use of higher cost next site of care facilities, both of which drove costs higher and in turn, lowered our savings rates.
Due to the passage of time between when we perform our services and the confirmation of results and subsequent cash settlement by CMS, COVID-19 and the aforementioned negative impacts have also negatively impacted our semi-annual cash flows related to the BPCI-A program.
We continue to monitor trends related to COVID-19, including the recent surge in variants, changes in CDC recommendations and their impact on results of operations and financial condition
on both of our operating segments.
Notes to the Condensed Consolidated Financial Statements (unaudited)
4.iBusiness
Combinations
Caravan Health Acquisition
On February 9, 2022, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Caravan Health, Inc., pursuant to which we acquired Caravan Health on March 1, 2022. Caravan Health is a leader in assisting ACOs to excel in population health management and value-based payment programs. The initial purchase price was approximately $i250.0 million,
subject to certain customary adjustments, and included approximately $i190.0 million in cash and approximately $i60.0 million
in our Class A common stock, comprised of i4,726,134 shares at $i12.5993 per share, which represents
the volume-weighted average price per share of our common stock for the five trading days ending three business days prior to March 1, 2022. In connection and concurrently with entry into the Merger Agreement, we entered into support agreements with certain shareholders of Caravan Health, pursuant to which such shareholders agreed that, other than according to the terms of its respective support agreement, it will not, subject to certain limited exceptions, transfer, sell or otherwise dispose of any of the Signify shares acquired for a period of up to five years following closing of the merger.
In addition to the initial purchase price, the transaction included contingent additional payments of up to $i50.0 million
based on certain future performance criteria of Caravan Health, which if conditions are met, may be paid in the second half of 2023. The preliminary fair value of the contingent consideration as of the acquisition date was estimated to be approximately $i30.5 million, which was estimated using a Black-Scholes option pricing model. See Note 13 Fair Value Measurements. Therefore, the total purchase consideration of the transaction
was determined to be $i287.4 million, which consisted of cash consideration, stock consideration, and potential contingent consideration.
We allocated the purchase price to the identifiable net assets acquired, based on the estimated fair values at the date of acquisition. The excess of the purchase price over the amount allocated to the identifiable assets and liabilities was recorded as goodwill. Goodwill represents the value of the acquired assembled
workforce and specialized processes and procedures and operating synergies, none of which qualified as separate intangible assets. All of the goodwill was assigned to our Episodes of Care Services segment. iNone of the goodwill is expected to be deductible for tax purposes.
We estimated the fair value of intangible assets acquired using estimates of future discounted cash flows to be
generated by the business over the expected duration of those cash flows. We based the estimated cash flows on projections of future revenue, operating expenses, capital expenditures, working capital needs and tax rates. We estimated the duration of the cash flows based on the projected useful lives of the assets acquired. The discount rate was determined based on specific business risk, cost of capital and other factors.
Notes to the Condensed Consolidated Financial Statements (unaudited)
The
purchase price allocation is preliminary and subject to change up to one year after the date of acquisition and could result in changes to the amounts recorded below. iThe preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed at the date of the acquisition was as follows:
The $i93.9
million of acquired intangible assets consists of customer relationships of $i69.8 million (i10-year
useful life), acquired technology of $i23.4 million (i5-year
useful life) and a tradename of $i0.7 million (i3-year
useful life).
The acquisition was not material to our Condensed Consolidated Statements of Operations. Therefore, pro forma results of operations related to this acquisition have not been presented. The financial results of Caravan Health have been included in our Condensed Consolidated Financial Statements since the date of the acquisition.
5.iVariable
Interest Entities
We consolidate our affiliates when we are the primary beneficiary. The primary beneficiary of a VIE is the party that has both the decision-making authority to direct the activities that most significantly impact the VIE’s economic performance and the right to absorb losses or receive benefits that could potentially be significant to the VIE.
Consolidated VIEs at March 31, 2022 and December 31, 2021 include iiseven/
physician practices that require an individual physician to legally own the equity interests as certain state laws and regulations prohibit non-physician owned business entities from practicing medicine or employing licensed healthcare providers. We have determined we are the primary beneficiary of these VIEs as we have the obligation to absorb the losses from and direct activities of these operations. As a result, these VIEs are consolidated and any non-controlling interest is not presented. Recourse of creditors to these VIEs is limited to the assets of the VIE entities, which totaled $i31.3 million and $i25.2
million at March 31, 2022 and December 31, 2021, respectively.
Notes to the Condensed Consolidated Financial Statements (unaudited)
i
The
carrying amount and classification of the VIEs’ assets and liabilities included in the Condensed Consolidated Balance Sheets, net of intercompany amounts, are as follows:
As
of March 31, 2022, Caravan Health is the sole member of ifour ACOs, which we have determined are VIEs. CMS offers an MSSP to ACOs, where the goal of the program is to reward the ACO participants when specific quality metrics are met and expenditures are lowered. The MSSPs have different risk models where the ACOs can either share in both savings and losses or share in only the savings. The governance structure of the VIEs does not provide
Caravan Health with the ultimate decision-making authority to direct the activities that most significantly impact the VIEs’ economic performance. Based on these ACOs’ operating agreements, the power to direct the VIEs’ operations is shared among the entities that make up the ACO Board of Directors, which is required to consist of at least i75% ACO participants (hospitals, clinics, etc.). As such, we have determined we are not the primary beneficiary of these VIEs, and therefore we do not consolidate the results of these
entities.
Caravan Health is ultimately liable for losses incurred by ione out of the ifour
ACOs owned by them. As of March 31, 2022 there was $i0.5 million included in restricted cash on our Condensed Consolidated Balance Sheets which relates to this VIE. The ACO has a master letter of credit with CMS as the recipient where the letter of credit is used as protection against unpaid losses, should the ACO fail to remit payment in the event that losses occur. The letter of credit is collateralized by the ACO members, by either cash remitted or subordinated
letters of credit. This restricted cash will only be used if an ACO member fails to remit payment in connection with a subordinated letter of credit.
iTwo of the ifour
VIEs are ACOs that are not part of an MSSP risk model where the losses are shared and the remaining VIE has a guarantor that has taken full responsibility of indebtedness of the ACO, and therefore, Caravan Health is not liable for its losses.
Notes to the Condensed Consolidated Financial Statements (unaudited)
During the three months ended March 31, 2022, we did not make any contributions to the unconsolidated VIEs for losses incurred. Our maximum
exposure to loss as a result of our involvement in these unconsolidated VIEs cannot be reasonably estimated as of March 31, 2022, as the shared losses are dependent on a number of variable factors, including estimates of patient attribution, expenditure data, benchmark data, inflation factors and CMS quality reporting. Losses incurred, if any, are determined once updated CMS reporting is provided, which is expected to be available in the third quarter of 2022. Under the provisions of the MSSP program, once a minimum shared loss rate of i2%
is exceeded, losses are calculated at a rate of 1 minus the final sharing rate, with a minimum shared loss rate of i40% and a maximum shared loss rate of i75%,
not to exceed i15% of the updated benchmark. Our current ACO contracts indicate that we will bear the risk beyond the first i1%
of potential losses not to exceed the MSSP maximum of i15%.
6.iRevenue
Recognition
i
Disaggregation of Revenue
We earn revenue from our itwo
operating segments, Home & Community Services and Episodes of Care Services, under contracts that contain various fee structures. Through our Home & Community Services segment, we offer health evaluations performed either within the patient’s home, virtually or at a healthcare provider facility, primarily to Medicare Advantage health plans (and to some extent, Medicaid). Additionally, we offer certain diagnostic screening and other ancillary services, and through our Signify Community solution, we offer access to services to address healthcare concerns related to social determinants of health. Through our Episodes of Care Services segment, we primarily provide services designed to improve the quality and efficiency of healthcare delivery by developing and managing episodic payment programs in partnership with healthcare providers, primarily under the BPCI-A program with
CMS. We also provide ACO services through our Caravan Health subsidiary, acquired in March 2022. Additionally, we provide certain complex care management services. All of our revenue is generated in the United States.
/
We are dependent on a concentrated number of payors and provider partners with whom we contract to provide our services, See Note 22 Concentrations.
i
The
following table summarizes disaggregated revenue from contracts with customers by source of revenue, which we believe best presents the nature, amount and timing of revenue.
Notes to the Condensed Consolidated Financial Statements (unaudited)
Performance Obligations
Episodes of Care Services
There have been no material changes to our revenue recognition and estimates, other than as described below related to the acquisition of Caravan Health. Caravan Health enters into contracts with customers to provide multiple services around the management of the ACO model. These include, but are not limited to, population health software, analytics, practice improvement, compliance, marketing, governance, surveys and licensing.
The overall objective of the services provided is to help the customer receive shared savings from CMS. Caravan Health enters into arrangements with customers wherein we receive a contracted percentage of each customer’s portion of shared savings if earned. We recognize shared savings revenue as performance obligations are satisfied over time, commensurate with the recurring ACO services provided to the customer over a 12-month calendar year period. The shared savings transaction price is variable, and therefore, we estimate an amount we expect to receive for each 12-month calendar year performance obligation period.
In order to estimate this variable consideration, management initially uses estimates of historical performance of the ACOs. We consider inputs such as attributed patients, expenditures, benchmarks and inflation factors. We adjust our estimates at the end of each reporting
period to the extent new information indicates a change is needed. We apply a constraint to the variable consideration estimate in circumstances where we believe the data received is incomplete or inconsistent, so as not to have the estimates result in a significant revenue reversal in future periods. Although our estimates are based on the information available to us at each reporting date, new and material information may cause actual revenue earned to differ from the estimates recorded each period. These include, among others, Hierarchical Conditional Category (“HCC”) coding information,quarterly reports from CMS, unexpected changes in attributed patients and other limitations of the program beyond our control. We receive final reconciliations from CMS and collect the cash related to shared savings earned annually in the third or fourth quarter of each year for the preceding calendar year.
The
remaining sources of Caravan Health revenue in our Episodes of Care Services segment are recognized over time when, or as, the performance obligations are satisfied and are primarily based on a fixed fee or per member per month fee. Therefore, they do not require significant estimates and assumptions by management.
Related Balance Sheet Accounts
i
The following table provides information about accounts included on the
Condensed Consolidated Balance Sheets.
(1)Accounts
receivable, net for Episodes of Care Services included $i1.6 million due from CMS as of March 31, 2022 primarily related to amounts not yet collected for the fifth reconciliation period of the BPCI-A program. As of December 31, 2021, accounts receivable, net for Episodes of Care Services included $i56.2
million due from CMS primarily related to the fifth reconciliation period of the BPCI-A program. Accounts receivable, net for Home & Community Services included $i51.1 million and $i3.7 million in amounts not yet billed to customers, as of March
31, 2022 and December 31, 2021, respectively. The remaining amount
Notes to the Condensed Consolidated Financial Statements (unaudited)
of accounts receivable for both Episodes of Care Services and Home & Community Services represent amounts to be received from customers. Home & Community Services accounts receivable
as of March 31, 2022 reflected strong IHE volume in the first quarter and a higher mix of in-person IHEs compared to vIHEs.
(2)Contract assets primarily represent management’s estimate of amounts we expect to receive under the BPCI-A program related to the next two reconciliation periods. As of March 31, 2022, contract assets covered episodes of care commencing in the period from April 2021 through March 2022. Estimates for program size and savings rate are based on information available as of the date of the financial statements. We record an estimate of revenue related to these performance obligations over the 13-month
period starting in the period the related episodes of care commence and through the estimated receipt of the semi-annual CMS reconciliation file. Any changes to these estimates based on new information will be recorded in the period such information is received. Total savings generated and revenue earned for the episodes of care in which a component of the contract asset recorded as of March 31, 2022 relates to, will be included in the semi-annual reconciliation expected from CMS during the second quarter of 2022. Contract assets for Episodes of Care Services segment also included $i10.5 million
related to estimated shared savings under the Caravan Health ACO services programs. Contract assets in the Home & Community Services segment of $i4.4 million as of March 31, 2022 represent management’s estimate of amounts to be received from clients as a result of certain service levels being achieved during the contractual period.
(3)Total shared savings payable is included in accounts
payable and accrued expenses on the Condensed Consolidated Balance Sheets. Shared savings payable for Episodes of Care Services included $i23.9 million due to CMS as of December 31, 2021, all of which was settled with CMS in the first quarter of 2022. Shared savings payable included $i35.6
million as of March 31, 2022 primarily related to the fifth reconciliation received in December 2021, which is expected to be paid to customers related to their portion of savings earned under the BPCI-A program. Additionally, there is $i1.8 million included in shared savings payable at March 31, 2022, which represents amounts withheld from customers under the BPCI-A program based on contractual withholding percentages. This amount has been received by us from CMS and is held as restricted cash. We expect to remit these amounts to customers
at the conclusion of the program, at which time both restricted cash and the liability will be reduced.
(4)Contract liabilities in our Episodes of Care Services segment represent management’s estimate of savings amounts we expect to share with our customers based on contractual shared savings percentages related to the amounts we expect to be entitled to receive under the BPCI-A program for the next two reconciliation periods. As of March 31, 2022, contract liabilities of $i39.2
million cover episodes of care commencing in the period from April 2021 through March 2022. These amounts offset the gross amount we expect to receive for the same period included in contract assets as of March 31, 2022.Contract liabilities in the Home & Community Services segment of $i4.8 million as of March
31, 2022 represent management’s estimate of potential refund liabilities due to certain clients as a result of certain service levels not being achieved during the contractual periods primarily due to COVID-19.
(5)Deferred revenue is included in other current liabilities on the Condensed Consolidated Balance Sheets and primarily relates to advance payments received from certain customers.
The table below summarizes the activity recorded in the contract asset and liability accounts for the periods presented.
Depreciation
and amortization expense for property and equipment, inclusive of amounts subsequently written off or disposed from accumulated depreciation, was $i2.2 million and $i2.0 million for the three months ended March 31, 2022 and 2021,
respectively. There was iino/
impairment of property and equipment during the three months ended March 31, 2022 or 2021.
Notes to the Condensed Consolidated Financial Statements (unaudited)
8.iLeases
New
Lease Guidance Adoption and Practical Expedients
We adopted ASC 842 as of January 1, 2022 using the optional transition method. Therefore, we did not restate comparative periods. Under this transition provision, we applied the legacy leases guidance, including its disclosure requirements, for the comparative periods presented.
ASC 842 includes practical expedient and policy election choices. We have elected the practical expedient transition package available in ASC Topic 842 and, as a result, did not reassess the lease classification of existing contracts or leases or the initial direct costs associated with existing leases. We made an accounting policy election
not to recognize right of use assets and lease liabilities for leases with a lease term of 12 months or less, including renewal options that are reasonably certain to be exercised, that also do not include an option to purchase the underlying asset that is reasonably certain of exercise. Instead, lease payments for these leases are recognized as lease expense on a straight-line basis over the lease term. We did not elect the hindsight practical expedient, and therefore we did not reassess our historical conclusions with regards to whether renewal option periods should be included in the terms of our leases.
Upon adoption on January 1, 2022, we recognized right-of-use assets and lease liabilities for operating leases of $i23.0 million
and $i35.6 million, respectively. The difference between the right-of-use asset and lease liability primarily represents the net book value of deferred rent and tenant improvement allowances recognized as of December 31, 2021, which was adjusted against the right-of-use asset upon adoption.
In addition, there was $i0.4 million
recorded as a reduction of retained earnings upon adoption. This primarily related to an asset that we ceased using prior to the adoption of ASC 842 and do not have the intent and ability to sublease since the remaining lease term is less than one year. We recognized a lease liability equal to the present value of the remaining lease payments under the contract; however, we did not recognize a corresponding right-of-use asset. The previously recognized cease-use liability as of December 31, 2021 was recognized as a reduction to the carrying amount of the right-of-use asset. As the cease-use liability balance was less than the carrying amount of the right-of-use asset, the remaining portion of the right-of-use asset not offset by the cease-use liability was written off as an adjustment to retained earnings since the cease-use date
of the asset occurred prior to adoption.
i
The following is a summary of the impact of ASC 842 adoption on our Condensed Consolidated Balance Sheet:
Notes to the Condensed Consolidated Financial Statements (unaudited)
Right-of-use Assets and Lease Liabilities
i
The following table presents our operating lease right-of-use assets and lease liabilities as of March 31, 2022. Current lease liabilities are included in other current liabilities on the Condensed Consolidated Balance Sheets.
For
the three months ended March 31, 2022, cash paid for amounts included in the measurement of operating lease liabilities was $i2.7 million.
Our operating lease expense is recorded as a component of SG&A in our Condensed Consolidated Statements of Operations. iThe
components of lease expense for the three months ended March 31, 2022 were as follows:
(1) Excludes short-term lease expense, which is not material
The following table presents the weighted average remaining lease term and discount rate of our operating leases as of March 31, 2022:
Weighted
Average Lease Term (Years)
i5.8
Weighted Average Discount Rate
i4.6
%
We
enter into contracts to lease office space and equipment with terms that expire at various dates through 2030. The lease term at the lease commencement date is determined based on the non-cancellable period for which we have the right to use the underlying asset, together with any periods covered by an option to extend the lease if we are reasonably certain to exercise that option, periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. We considered a number of factors when evaluating whether the options in our lease contracts were reasonably certain of exercise, such as length of time before option
exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to overall operations, costs to negotiate a new lease, and any contractual or economic penalties.
Notes to the Condensed Consolidated Financial Statements (unaudited)
i
As
of March 31, 2022, maturities of our operating lease liabilities are as follows:
Remainder of 2022
$
i7.2
2023
i8.3
2024
i4.8
2025
i4.1
2026
i3.4
Thereafter
i10.6
Total
lease payments
i38.4
Less: imputed interest
(i5.1)
Present
value of operating lease liabilities
$
i33.3
/
Effective October 1, 2021, we entered into a lease agreement for a facility in Oklahoma City, OK. The lease term is i7.25
years, with itwoi5-year options to renew, and total lease payments are expected to be approximately $i4.2 million.
The lessor and its agents are currently building this retail space and the lease is expected to commence once the construction of the asset has been completed. We expect commencement in the second quarter of 2022. As the lease has not yet commenced, it is not included in the right-of-use asset or lease liabilities recorded as of March 31, 2022. In addition, we entered into a lease agreement for a facility in New York, NY which is expected to commence February 1, 2024, once our current lease for this facility expires on January 31, 2024. The lease term is i5.75
years, with ionei5-year option to renew, and total lease payments are expected to be approximately $i22.7 million.
Disclosures
Related to Periods Prior to Adoption of ASC 842
i
As of December 31, 2021, future minimum lease payments under non-cancellable operating leases were as follows:
2022
$
i10.2
2023
i8.7
2024
i6.1
2025
i9.3
2026
i8.6
Thereafter
i21.5
$
i64.4
/
9.iIntangible
Assets
i
Intangible assets were as follows as of each of the dates presented:
Notes to the Condensed Consolidated Financial Statements (unaudited)
We capitalized $i6.8 million and $i5.7
million of internally-developed software costs for the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022, we acquired $i93.9 million of intangible assets in connection with the acquisition of Caravan Health (see Note 4. Business
Combinations), which included preliminary values for customer relationships of $i69.8 million (i10-year
useful life), acquired technology of $i23.4 million (i5-year
useful life) and a tradename of $i0.7 million (i3-year
useful life).
There was iino/ impairment
of intangible assets for the three months ended March 31, 2022 or 2021.
Amortization expense for intangible assets, inclusive of amounts subsequently written off from accumulated amortization, was $i15.8 million and $i14.7
million for the three months ended March 31, 2022 and 2021, respectively. iExpected amortization expense as of March 31, 2022 related to intangible assets, including internal-use software development costs, was as follows:
(in
millions)
Remainder of 2022
$
i53.4
2023
i65.4
2024
i50.6
2025
i43.8
2026
i43.1
Thereafter
i283.9
$
i540.2
10.iGoodwill
i
The
change in the carrying amount of goodwill for each reporting unit is as follows:
As
of March 31, 2022 and December 31, 2021, the effective interest rate on the 2021 Term Loan borrowings was i4.26% and i3.75%,
respectively.
The 2021 Credit Agreement is secured by substantially all of the assets of Signify and its subsidiaries. The 2021 Credit Agreement contains customary representations and warranties as well as customary affirmative and negative covenants and events of default. Negative covenants include, among others (and in each case subject to certain exceptions), limitations on incurrence of liens by Signify and its restricted subsidiaries, limitations on incurrence of indebtedness by Signify and its restricted subsidiaries, limitations on making dividends and other distributions, limitations on engaging in asset
sales, limitation on making investments, limitations on engaging in transactions with affiliates. As a result of these restrictions, substantially all of the subsidiary net assets are deemed restricted as of December 31, 2021. Additionally, the 2021 Credit Agreement includes a requirement that the consolidated first lien net leverage ratio (as defined in the 2021 Credit Agreement) as of the end of any fiscal quarter is not greater than i4.50 to 1.00 if on the last day of such fiscal quarter the Revolving Facility and letters
of credit outstanding exceeds i35% of the total amount of Revolving Facility commitments at such time.As of March 31, 2022, we were in compliance with all financial covenants.
We currently have ino
borrowings outstanding under the Revolving Facility. As of March 31, 2022, we had $i172.8 million available borrowing capacity under the Revolving Facility, as the borrowing capacity is reduced by outstanding letters of credit.
i
The
aggregate principal maturities of long-term debt due subsequent to March 31, 2022 are as follows:
There
were no transfers between Level 1 and Level 2, or into or out of Level 3, during the three months ended March 31, 2022 or 2021.
Fair value of assets measured on a non-recurring basis include intangible assets when there is an impairment triggering event. See Note 8 Intangible Assets.
i
The
changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:
Grant
date fair value estimate recorded as reduction to revenue
i4.9
i4.9
Grant
date fair value estimate of EAR letter agreement recorded as reduction to revenue
i1.6
i—
Remeasurement
of fair value of customer EAR agreements included in other expense (income), net
i29.2
i56.8
Remeasurement
of fair value of EAR letter agreement, included in other expense (income), net
(i0.3)
i—
Balance
at end of period
$
i84.0
$
i83.3
i
The
valuation techniques and significant unobservable inputs used in recurring Level 3 fair value measurements were as follows as of March 31, 2022:
Fair Value (in millions)
Valuation
Technique
Significant Unobservable Inputs
Assumption
Customer equity appreciation rights
$
i82.7
Monte
Carlo
Volatility
i55.0%
Dividend yield
i0%
Risk-free
rate
i2.43%
Expected term (years)
i3.25
EAR
Letter Agreement
$
i1.3
Monte Carlo
Volatility
i55.0%
Dividend
yield
i0%
Risk-free rate
i2.43%
Expected
term (years)
i3.25
Consideration due to sellers
$
i30.6
Black-Scholes
Volatility
i13.5%
Discount
Rate
i2.30%
Risk Free Rate
i0.51%
Credit
Spread
i4.90%
Expected term (years)
i1.58
Consideration
due to sellers
$
i—
Discounted approach
Discount Rate
i5.0%
Fair
value of the contingent consideration related to the Caravan Health acquisition (see Note 4. Business Combinations) was measured using the Black-Scholes option pricing model, which uses certain assumptions to estimate the fair value, including long-term financial forecasts, expected term until payout, volatility, discount rate, credit spread, and risk-free rate. The expected volatility and discount rate as of the acquisition date were calculated using comparable peer companies, adjusted for Caravan Health’s operational leverage. The risk-free interest rate is based on the U.S. Treasury rates that are commensurate with the term of the contingent consideration.As of March 31, 2022, the amount recognized for the contingent consideration arrangement, the range of outcomes, and the
assumptions used to develop the estimates did not change compared to those used to estimate Caravan Health’s initial fair value.
Notes to the Condensed Consolidated Financial Statements (unaudited)
The valuation techniques and significant unobservable inputs used in recurring Level 3
fair value measurements were as follows as of December 31, 2021:
Fair Value (in millions)
Valuation Technique
Significant
Unobservable Inputs
Assumption
Customer equity appreciation rights
$
i48.6
Monte Carlo
Volatility
i50.0%
Dividend
yield
i0%
Risk-free rate
i1.05%
Expected
term (years)
i3.5
Fair
Value (in millions)
Valuation Technique
Significant Unobservable Inputs
Discount Rate
Consideration due to sellers
$
i—
Discounted
approach
Discount Rate
i5.0%
The fair value of our debt is measured at Level 3 and is determined based on fluctuations in current interest rates, the trends in market yields of debt instruments with similar credit ratings, general economic conditions and other
quantitative and qualitative factors. The carrying value of our debt approximates its fair value as it is variable-rate debt.
The carrying amounts of accounts receivable and accounts payable approximate their fair value because of the relatively short-term maturity of these instruments.
14.iShareholders’
Equity
See Note 1 Nature of Operations for details of the Reorganization Transactions effective in February 2021 in connection with our IPO.
Initial Public Offering
On February 16, 2021, Signify Health closed an IPO of i27,025,000
shares of its Class A common stock at a public offering price of $i24 per share, which included i3,525,000 shares issued pursuant to the full exercise of
the underwriters’ over-allotment option. Signify Health received gross proceeds of $i648.6 million, which resulted in net cash proceeds of $i609.7
million after deducting underwriting discounts and commissions of $i38.9 million and before fees and expenses incurred in connection with the IPO incurred and paid for by Cure TopCo. Signify Health used the proceeds to purchase newly-issued membership interests from Cure TopCo at a price per interest equal to the IPO price of its Class A common stock, net of the underwriting discounts and commissions.
In connection with the Reorganization Transactions and IPO, our certificate of incorporation was amended and restated to, among other things, authorize the issuance of itwo classes of common stock: Class A common stock and Class B common stock. The Amended and Restated Certificate of Incorporation authorizes i1,000,000,000
shares of Class A common stock, par value $i0.01 per share and i75,000,000 shares of Class B common stock, par value $i0.01
per share. The Amended and Restated Certificate of Incorporation also authorizes up to i50,000,000 shares of preferred stock, par value of $i0.01
per shares, none of which have been issued.
Class A Common Stock
Holders of shares of Class A common stock are entitled to ione vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. The holders of Class A common stock do not have cumulative voting rights in the election of directors.
Notes to the Condensed Consolidated Financial Statements (unaudited)
Holders of shares of Class A common stock are entitled to receive dividends when and if declared by the board of directors out of funds legally available, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock.
Upon liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of Class A common stock will be entitled to receive pro rata our remaining assets available for distribution.
All
shares of Class A common stock outstanding are fully paid and non-assessable. The Class A common stock are not subject to further calls or assessments. The rights, powers and privileges of Class A common stock are subject to those of the holders of any shares of preferred stock.
Class B Common Stock
Each share of Class B common stock entitles its holder to ione vote per share on all matters submitted to a vote of the stockholders. If
at any time the ratio at which LLC Units are redeemable or exchangeable for shares of Class A common stock changes from ione-for-one, the number of votes to which Class B common stockholders are entitled will be adjusted accordingly. The holders of Class B common stock do not have cumulative voting rights in the election of directors.
Except for transfers to Signify Health pursuant to the Cure TopCo Amended LLC Agreement or to certain permitted transferees, the LLC Units and corresponding shares
of Class B common stock may not be sold, transferred or otherwise disposed of. Holders of shares of Class B common stock will vote together with holders of Class A common stock as a single class on all matters on which stockholders are entitled to vote, except as otherwise required by law.
The Class B common stock is not entitled to economic interests in Signify Health. Holders of Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation or winding up of Signify Health. However, if Cure TopCo makes distributions to Signify Health, the other holders of LLC Units, including the Continuing Pre-IPO LLC Members, will be entitled to receive distributions pro rata in accordance with the percentages of their respective LLC Units. The Class B common stock is not subject to further calls or assessment.
Cure
TopCo, LLC Recapitalization
As noted above, in connection with our IPO, the limited liability company agreement of Cure TopCo was amended and restated (the “Cure TopCo LLCA”) to, among other things, convert all outstanding equity interests into LLC Units and appoint us as the sole managing member of Cure TopCo.
Under the Cure TopCo LLCA, holders of LLC Units have the right to require Cure TopCo to redeem all or a portion of their LLC Units for newly issued shares of our Class A common stock on a ione-for-one
basis or a cash payment equal to the volume-weighted average market price of one share of our Class A common stock for each LLC Unit redeemed. This will result in the recognition of a contingently redeemable noncontrolling interest in Cure TopCo held by the Continuing Pre-IPO LLC Members, which will be redeemable, at the election of Signify Health, for shares of Class A common stock on a ione-for-one basis or a cash payment in accordance with the terms of the Cure TopCo LLCA and which, if the redeeming member is an affiliate, the decision to redeem in cash or shares will
be approved by the disinterested members of the Audit Committee.
Cure TopCo Membership Units
The LLC Units of Cure TopCo do not have voting interests in Cure TopCo. The LLC Units do have rights with respect to the profits and losses and distributions of Cure TopCo as set forth in the Cure TopCo LLCA.
15.iNoncontrolling
Interest
We are the sole manager of Cure TopCo and, as a result of this control, and because we have a substantial financial interest in Cure TopCo, we consolidate the financial results of Cure TopCo into our Condensed Consolidated Financial Statements. The contingently redeemable noncontrolling interest represents the economic interests of Cure TopCo held by the holders of LLC Units other than the membership units held by us. Income or loss is attributed to
Notes to the Condensed Consolidated Financial Statements (unaudited)
the
noncontrolling interests based on the relative percentages of LLC Units held by us and the other holders of LLC Units during the period. As such, future redemptions or direct exchanges of LLC Units will result in a change in ownership and reduce or increase the amount recorded as noncontrolling interests and increase or decrease additional paid-in capital in the Condensed Consolidated Balance Sheets.
i
The following table
summarizes the ownership interests in Cure TopCo as of March 31, 2022:
LLC Units
Ownership Percentage
Number of LLC Units held by Signify Health, Inc.
i176,232,513
i75.5%
Number
of LLC Units held by noncontrolling interests
i57,313,051
i24.5%
Total
LLC Units outstanding
i233,545,564
i100.0%
/
LLC
Units held by the Continuing Pre-IPO LLC Members are redeemable or exchangeable for, at our election and with appropriate approvals, newly issued shares of Class A common stock on a ione-for-one basis or a cash payment in accordance with the terms of the Cure TopCo LLCA.
During the three months ended March 31, 2022, i18,076
LLC units were exchanged by Continuing Pre-IPO LLC Members, and shares of Class A common stock were issued on a ione-for-one basis.
16.iEquity-Based
Compensation
On March 1, 2022, our Board of Directors approved amendments to certain outstanding equity award agreements subject to performance-based vesting criteria. The equity awards were amended with an effective date of March 7, 2022, and include i3,572,469
outstanding LLC Incentive Units and i817,081 outstanding stock options. The amendments added an alternative iitwo-year/
service-vesting condition to the performance-vesting criteria, which, through the effective date of the amendment, were considered not probable of occurring and therefore we had not previously recorded any expense related to these awards. The amended equity awards will now vest based on the satisfaction of the earlier to occur of 1) a iitwo
year/ service condition, with ii50/%
vesting in each of March 2023 and March 2024 or 2) the achievement of the original performance vesting criteria. As a result of this amendment, which results in vesting that is considered probable of occurring, we began to record equity-based compensation expense for these amended equity awards in March 2022. The equity-based compensation expense related to these amended awards is based on the fair value as of the effective date of the amended equity awards and will be recorded over the iitwo
year/ service period.
2021 Long-Term Incentive Plan
In January 2021, our Board of Directors adopted the 2021 Long-Term Incentive Plan (the “2021 LTIP”) which became effective in connection with the IPO and provides for the grant of equity-based awards to employees, consultants, service providers and non-employee directors. At inception, there were i16,556,298
shares of Class A common stock available for issuance under the 2021 LTIP. The share pool will be increased on the first day of each year by the least of (i) i14,191,113 shares of Class A common stock, (ii) i3%
of the aggregate number of shares of Class A common stock and shares of Class B common stock outstanding (on a fully diluted basis) on the last day of the immediately preceding fiscal year and (iii) an amount determined by the Board of Directors. Any shares underlying substitute awards, shares remaining available for grant under a plan of an acquired company and awards (including pre-IPO awards (as defined in the 2021 LTIP)) that are forfeited, cancelled, expired, terminated or are otherwise lapsed, in whole or in part, or are settled in cash or withheld in respect of taxes, will become available for future grants under the 2021 LTIP. As of December 31, 2021 the total number of shares available for future issuance under the 2021 LTIP was i15,246,831.
On January 1, 2022, the share pool was increased by i3% of the aggregate number of Class A common stock and Class B common stock outstanding, or i7,255,410
shares of Class A common stock pursuant to the automatic increase provision described herein.
Notes to the Condensed Consolidated Financial Statements (unaudited)
Stock Options
The total fair value on March 7, 2022, the amendment effective date, based on a Black-Scholes value of $i8.49,
for the March 2022 amended stock options as described above, was $i6.9 million, of which we recorded $i0.2
million during the three months ended March 31, 2022. Subsequent to these amendments, there are no longer any stock options outstanding that are subject only to performance-based vesting conditions that are not probable of occurring.
i
The following is a summary of stock option activity for awards subject to time-based vesting for the three months ended March 31, 2022:
During the three months ended March 31, 2022, we recognized $i3.1 million and $i0.2
million, of equity-based compensation expense included in SG&A expense and Service expense, respectively, on the Condensed Consolidated Statements of Operations related to stock options and RSUs. During the three months ended March 31, 2021, we recognized $i1.1 million of equity-based compensation expense included in SG&A expense on the Condensed Consolidated Statements of Operations related to stock options and RSUs.
As
of March 31, 2022, we had total unrecognized compensation expense of $i89.8 million related to i9,914,736
unvested time-based stock options and RSUs which we expect to recognize over a weighted average period of i1.9 years.
Notes
to the Condensed Consolidated Financial Statements (unaudited)
Employee Stock Purchase Plan
During the three months ended March 31, 2022, we recognized $i0.1 million of equity-based compensation expense included in SG&A expense on the Condensed Consolidated Statements of Operations related to the ESPP.
LLC
Incentive Units
The total fair value on the amendment date for the March 2022 amended LLC Incentive Units as described above was based on the closing stock price on the amendment date of $i14.19, resulting in total fair value of $i50.7 million,
of which we recorded $i1.7 million in equity-based compensation expense during the three months ended March 31, 2022.
As of March 31, 2022, i6,941,723
of the outstanding LLC units are unvested. This includes i2,279,916 that were not amended and remain subject to performance-based vesting criteria which were not probable of occurring as of March 31, 2022.
In addition to the expense noted above related to those
awards amended in March 2022, during the three months ended March 31, 2022 and 2021, we recognized $i1.3 million and $i1.4
million, respectively, of equity-based compensation expense related to LLC Units included in SG&A expense on the Condensed Consolidated Statements of Operations, respectively.
As of March 31, 2022, there was $i53.0 million of total unrecognized compensation expense related to unvested time-based
Incentive Units expected to be recognized over a weighted average period of i1.0 year. Additionally, there was approximately $i4.3 million
of unrecognized compensation expense related to Incentive Units with performance-based vesting, in which the vesting conditions were not probable of occurring as of March 31, 2022.
17.iLoss Per Share
Basic loss per share of Class A common stock is computed by dividing net
loss attributable to Signify Health by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share of Class A common stock is computed by dividing net loss attributable to Signify Health by the weighted-average number of shares of Class A common stock outstanding adjusted to give effect to potentially dilutive securities.
Notes to the Condensed Consolidated Financial Statements (unaudited)
i
The
following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock for the three months ended March 31, 2022 and 2021. The basic and diluted loss per share for the three months ended March 31, 2021 only includes the period from February 12, 2021 to March 31, 2021, which represents the period wherein we had outstanding Class A common stock.
Less:
Net loss attributable to pre-Reorganization Transactions
—
(i17.2)
Less: Net loss attributable to the noncontrolling interest
(i5.4)
(i11.3)
Net
loss attributable to Signify Health, Inc.
$
(i10.9)
$
(i23.2)
Weighted
average shares of Class A common stock outstanding - Basic
i172,761,665
i165,486,015
Earnings
(loss) per share of Class A common stock - Basic
$
(i0.06)
$
(i0.14)
Earnings
(loss) per share of Class A common stock - Diluted
$
(i0.06)
$
(i0.14)
/
Shares
of Class B common stock do not participate in our earnings or losses and are therefore not participating securities. As such, separate presentation of basic and diluted loss per share of Class B common stock under the two-class method has not been presented. Shares of our Class B common stock and the corresponding LLC Units are, however, considered potentially dilutive shares of Class A common stock. LLC Units of Cure TopCo participate in the earnings of Cure TopCo and therefore, our portion of Cure TopCo’s earnings (loss) per share has been included in the net loss attributable to Signify Health in the calculation above. LLC Units held by the Continuing Pre-IPO LLC Members are redeemable in accordance with the Cure TopCo LLCA, at the election of Signify Health, for shares of Class A common stock on a ione-for-one
basis or a cash payment.
The potential dilutive effect of LLC Units are evaluated under the if-converted method. The potential dilutive effect of stock options and RSUs are evaluated under the treasury stock method.
i
The following table summarizes the stock options, RSUs and LLC Units that were anti-dilutive for the periods indicated. The effects of each would
have been anti-dilutive as we recorded a net loss in each of the periods. As a result, these shares, which were outstanding, were excluded from the computation of diluted loss per share for the periods indicated.
During the three months ended March 31, 2022, we incurred $i3.2 million of transaction-related expenses in connection with the acquisition of Caravan Health and other corporate development activities, such as potential mergers and acquisitions, strategic investments and other similar activities. These transaction-related expenses primarily related to consulting and other professional services expenses, as well as certain integration-related
expenses following the acquisition of Caravan Health.
Notes to the Condensed Consolidated Financial Statements (unaudited)
For the three months ended March 31, 2021, we incurred $i0.9
million of transaction-related expenses related to expenses incurred in connection with corporate development activities, such as potential mergers and acquisitions, strategic investments and other similar activities. These transaction-related expenses related to consulting, compensation, and integration-type expenses. Additionally, for the three months ended March 31, 2021, we incurred $i4.7 million of costs in connection with our IPO.
19.iCommitments
and Contingencies
Letters of Credit
As of March 31, 2022, we had outstanding letters of credit totaling $i12.2 million, including $i3.0 million
related to leased properties and $i9.2 million in favor of CMS, which are required in the event of a negative outcome on certain episodes of care within the BPCI-A program and we do not settle the related amounts owed to CMS. This amount reduces the borrowing amount available to us under our Revolving Facility as ofMarch 31, 2022. See Note 12 Long-Term Debt for the total value of letters of credit under this
facility. However, the terms of BPCI-A also require that certain partners provide a related reciprocal letter of credit for the majority of this amount. In February 2022, the entire $i8.8 million of the reciprocal letters of credit were released as a result of collateral being available under the new credit agreement.
Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources
are recorded when it is probable a liability has been incurred and the amount of the liability can be reasonably estimated. We are involved in various lawsuits, claims and administrative proceedings arising in the normal course of business. In management’s opinion, the ultimate resolution of these matters will not materially adversely affect our financial position, results of operations or cash flows.
Sales Tax Reserve
During the year ended December 31, 2019, it was determined that certain Episodes of Care Services may be subject to sales tax in certain jurisdictions. Historically, we had not collected sales tax from our Episodes of Care Services customers as we believed the services were not taxable. As of March 31,
2022 and December 31, 2021, we had a liability of $i1.8 million and $i1.6 million, respectively, for potential sales tax exposure related to services performed in 2016 through the second
quarter of 2020, included in other current liabilities on the Condensed Consolidated Balance Sheets. During the three months ended March 31, 2022, we received final audit settlement with certain states that led to $i0.2 million recorded as an increase to SG&A expense on the Condensed Consolidated Statement of Operation. We are in the process of settling the remaining potential exposure with the various states and we began collecting sales tax from customers in the second quarter of 2021 for 2020 services.
Equity
Appreciation Rights
As of March 31, 2022, there was approximately $i14.8 million of original grant date fair value unrecognized related to the original customer EAR agreements, which we expect to record as a reduction of revenue through the end of 2022. We remeasure the fair value of the outstanding EAR agreements at the end of each reporting
period and record any changes in fair value to other expense (income), net in our Condensed Consolidated Statement of Operations. See Note 13 Fair Value Measurements for changes in estimated fair value and valuation techniques used to estimate the EAR.
In December 2021, we and our customer agreed to extend our existing commercial arrangements through the middle of 2026 and established targets for the minimum number of IHEs to be performed on behalf of the customer each year (the “Volume Targets”). We also entered into a letter agreement (the “EAR Letter Agreement”) with the customer that provides that, in the event of a change in control of the Company or certain other corporate transactions,
and subject to achievement of the Volume Targets, if the aggregate amount paid under the EARs prior to and in connection with such event (the “Aggregate EAR Value”) is less than $i118.5 million, then the customer will be paid the difference between $i118.5
million and the Aggregate EAR Value. The EAR Letter Agreement is a separate equity value-linked instrument, independent from the original EARs. The grant date fair value is
Notes to the Condensed Consolidated Financial Statements (unaudited)
determined based on an option pricing model. Similar to the original EARs, we will record the initial grant date fair value as a reduction to revenue over the performance period, beginning in 2022. Estimated changes in fair market value will be recorded each accounting period based on management’s
current assumptions related to the underlying valuation approaches as other (income) expense, net on the Condensed Consolidated Statement of Operations. The grant date fair value of the EAR Letter Agreement was estimated to be $i76.2 million and will be recorded as a reduction of revenue through June 30, 2026, coinciding with
the service period. iAs of March 31, 2022, there was approximately $i74.6
million of original grant date fair value unrecognized related to the EAR Letter Agreement, which we expect to record as a reduction of revenue as follows:
Remainder of 2022
$
i4.7
2023
i20.0
2024
i20.0
2025
i19.9
2026
i10.0
Total
$
i74.6
We
remeasure the fair value of the outstanding EAR Letter Agreement at the end of each reporting period and record any changes in fair value to other expense (income), net in our Condensed Consolidated Statement of Operations. See Note 13 Fair Value Measurements for changes in estimated fair value and valuation techniques used to estimate the fair value of the EAR Letter Agreement.
Synthetic Equity Plan
In connection with our IPO in February 2021, the Synthetic Equity Plan (“SEP”) was amended to, among other things, remove the change in control payment condition and provide for cash settlement upon each vesting event based on a i30
trading day volume weighted average price of our Class A common shares. Prior to this amendment, the vesting criteria were not probable of occurring and we had not recognized any compensation expense related to these awards. Concurrent with the February 2021 amendment, we began to record compensation expense and a current liability beginning in the first quarter of 2021 related to outstanding synthetic equity awards (“SEUs”) subject to time-based vesting. The liability and expense are adjusted each reporting period based upon actual cash settlements and the underlying value of our Class A common stock. The SEU liability is included in accounts payable and accrued expenses on our Condensed Consolidated Balance Sheet. We have not recorded any expense related to the outstanding SEUs subject to performance-based vesting as the vesting criteria were not probable of occurring as of March 31, 2022. Most of the outstanding
SEUs subject to performance-based vesting were amended in March 2022, to add a time-based vesting component and therefore, we began recognizing compensation expense related to these outstanding SEUs over the amended service period.
As of March 31, 2022, i198,668
SEUs were subject to time-based vesting and i9,152 synthetic equity units outstanding are subject to performance-based vesting.
i
The
following table summarizes the change in the SEU liability:
Notes to the Condensed Consolidated Financial Statements (unaudited)
Contingent Consideration
As of March 31, 2022, we recorded $i30.6 million in long-term contingent consideration on our Condensed Consolidated Balance Sheets related to potential payments due upon the completion of certain
performance targets in connection with our acquisition of Caravan Health in March 2022. See Note 4 Business Combinations. If contingent milestones are achieved under the terms of the Merger Agreement, we expect to make any payments due during the second half of 2023.
20.iIncome Taxes
Income
tax benefit for the three months ended March 31, 2022 and 2021, was $i6.0 million and $i9.9 million, respectively.
Our effective tax rate for the three months ended March 31, 2022 was i27.0% compared to i16.1% for the three months
ended March 31, 2021. Our effective tax rate for the three months ended March 31, 2022 is higher than the U.S. Federal statutory rate of 21% primarily due to state taxes and non-deductible items partially offset by amounts not subject to income taxes related to the non-controlling interest. Our effective tax rate for the three months ended March 31, 2021 was less than the U.S. Federal statutory rate of 21% primarily due to not being subject to income taxes on the portion of earnings that are attributable to the non-controlling interest and loss in the pre-reorganization period partially offset by state taxes.
Uncertain Tax Provisions
We evaluate and account
for uncertain tax positions taken or expected to be taken on an income tax return using a two-step approach. Step one, recognition, occurs when we conclude that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Step two, measurement, determines the amount of benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when we subsequently determine that a tax position no longer meets the more likely-than-not threshold of being sustained. We record interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of the income tax provision.
We have evaluated our tax positions
and have identified uncertain tax positions for which a reserve should be recorded. Accordingly, a provision for uncertainties in income taxes of $i0.3 million has been recorded and is included in other noncurrent liabilities on our Condensed Consolidated Balance Sheet as of March 31, 2022.
Tax Receivable Agreement
In
February 2021, in connection with the Reorganization Transactions and IPO, we entered into the Tax Receivable Agreement (the “TRA”), which obligates us to make payments to the Continuing Pre-IPO LLC Members, the Reorganization Parties, Optionholders (as defined in the TRA) of the Blocker Companies at the time of the Mergers, holders of synthetic equity units and any future party to the TRA (collectively, the “TRA Parties”) in the aggregate generally equal to i85% of the applicable cash savings that we actually realize as a result of
(i) certain favorable tax attributes acquired from the Blocker Companies in the Mergers (including net operating losses, the Blocker Companies’ allocable share of existing tax basis and refunds of Blocker Company taxes attributable to pre-Merger tax periods), (ii) increases in our allocable share of existing tax basis and tax basis adjustments that may result from (x) future redemptions or exchanges of LLC Units by Continuing Pre-IPO LLC Members for cash or Class A common stock, (y) the IPO Contribution and (z) certain payments made under the TRA and (iii) deductions in respect of interest and certain compensatory payments made under the TRA. We will retain the benefit of the remaining i15%
of these tax savings.
As of March 31, 2022, we had a liability of $i56.3 million related to the projected obligations under the TRA. TRA related liabilities are classified as current or noncurrent based on the expected date of payment. During the three months ended March 31, 2022, we recorded an immaterial increase in the TRA liability. As of March 31, 2022, there are no amounts
due within 12 months and therefore the entire liability is included in Tax receivable agreement liability within noncurrent liabilities on our Condensed Consolidated Balance Sheet.
Notes to the Condensed Consolidated Financial Statements (unaudited)
21.iSegment
Reporting
Operating segments are components of an enterprise for which separate financial information is available and evaluated regularly by our Chief Operating Decision Maker in deciding how to allocate resources and in assessing financial performance. Management views our operating performance in itwo reportable segments: Home & Community Services and Episodes of Care Services.
We
evaluate the performance of each segment based on segment revenue and adjusted EBITDA. The operating results of the reportable segment are based on segment adjusted EBITDA, which includes revenue and expenses incurred by the segment, as well as an allocation of shared expenses. Shared expenses are generally allocated to each segment based on the segments’ proportionate employee headcount. Certain costs are not allocated to the segments, as described below, as these items are not considered in evaluating the segment’s overall performance.
See Note 6 Revenue Recognition for a summary of segment revenue by product type for the three months ended March 31, 2022 and 2021. iOur
operating segment results for the periods presented were as follows:
Less:
reconciling items to loss before income taxes:
Unallocated costs (1)
i45.3
i72.5
Depreciation
and amortization
i18.0
i16.7
Interest
expense
i4.0
i6.8
Loss
before income taxes
$
(i22.3)
$
(i61.6)
(1)
Unallocated costs as follows:
Other (income) expense, net (2)
i28.8
i56.7
Equity-based
compensation
i6.5
i2.5
SEU
Expense
i0.1
i1.5
Customer
equity appreciation rights
i6.5
i4.9
Transaction-related
expenses
i3.2
i5.6
Non-allocated
costs (3)
i0.2
i1.3
Total
unallocated costs
$
i45.3
$
i72.5
(2)
Other (income) expense, net includes the remeasurement of the fair value of the outstanding customer EARs and EAR Letter Agreement as well as interest and dividends earned on cash and cash equivalents.
(3) Non-allocated costs included remeasurement of contingent consideration and certain non-recurring expenses, including those associated with the closure of certain facilities, the sale of certain assets, one-time expenses related to the COVID-19 pandemic and the early termination of certain contracts. These costs are not considered by our Chief Operating Decision Maker in making resource allocation decisions.
Notes to the Condensed Consolidated Financial Statements (unaudited)
Our Chief Operating Decision Maker does not receive or utilize asset information to evaluate performance of operating segments. Accordingly, asset-related information has not been presented.
22.iConcentrations
During the normal course of operations, we maintain cash in bank accounts which exceed federally insured amounts. We have not experienced any losses in such accounts and do not believe we are exposed to any significant credit risk related to cash.
Accounts receivable potentially subject us to concentrations of credit risk. Management believes that its contract acceptance, billing and collection policies are adequate to minimize potential credit risk. We continuously evaluate the credit worthiness of our customers’ financial condition and generally do not require collateral.
We are dependent on a concentrated number of
payors and provider partners with whom we contract to provide IHEs and other services. A significant portion of our revenues are generated from a small number of customers. iOur largest customers accounted for the following percentages of total net revenue:
*Revenue from this customer was less than 10% of total net revenue during the period noted.
In addition, the revenue from our top ten customers accounted for approximately i84%
of our total revenue for the three months ended March 31, 2022.
As of March 31, 2022, we had three customers which accounted for approximately i27%, i19%
and i10%, respectively, of accounts receivable. As of March 31, 2021, we had three customers which accounted for approximately i18%, i12%,
and i10%, respectively, of accounts receivable.
While CMS is not our customer, a majority of the revenue generated by Episodes of Care Services is under the CMS administered BPCI-A program and payments are received under this program in certain cases from CMS rather than directly from the customer. During the three months ended March 31, 2022, approximately 10% of total consolidated revenue was generated from the BPCI-A program.
23.iRelated
Party Transactions
In connection with the Reorganization Transactions, we entered into several agreements with various parties including Cure TopCo, New Mountain Capital and its affiliates, certain members of management and other shareholders. These include the Reorganization Agreement, the Cure TopCo, LLC Agreement, the TRA, the Registration Rights Agreement and the Stockholders' Agreement, all of which are fully described in our 2021 Annual Report on Form 10-K. See Note 1 Nature of Operations for further details on the Reorganization Transactions. See Note 14 Shareholders' Equity for additional information
on the Cure TopCo, LLC Recapitalization. See Note 20 Income Taxes for additional information on the TRA.
24.iSubsequent Events
Effective April 1, 2022, we entered into a new lease agreement for a facility in Galway, Ireland.
The lease term is i15 years with an option to terminate after i10 years, and total lease payments are expected to be approximately $i7.0 million
over i10 years, or $i11.1 million over i15
years.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Note Regarding Forward-Looking Statements
We have made statements in this Quarterly Report on Form 10-Q, including matters
discussed under Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations, Part II, Item 1. Legal Proceedings, Part II, Item 1A. Risk Factors, and in other sections of this Quarterly Report on Form 10-Q, that are forward-looking statements. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q are forward-looking statements. These statements may be preceded by, followed by or include the words “may,”“might,”“will,”“should,”“expects,”“plans,”“anticipates,”“believes,”“estimates,”“predicts,”“potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated
trends in our business, our ability to realize synergies in our businesses and our plans to expand our investment in value-based payment programs and in our product portfolio. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under Part II, Item 1A. Risk Factors and Part I, Item 1A. Risk Factors of our 2021 Annual Report on Form 10-K.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person
assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include:
•the COVID-19 pandemic and whether the pandemic will continue to subside in 2022;
•our dependence upon a limited number of key customers;
•our dependence on certain key government programs;
•our failure to maintain and grow our network of high-quality providers;
•our failure to continue to innovate and provide services that are useful to customers and
achieve and maintain market acceptance;
•our limited operating history with certain of our solutions;
•our failure to compete effectively;
•the length and unpredictability of our sales cycle;
•failure of our existing customers to continue or renew their contracts with us;
•failure of service providers to meet their obligations to us;
•seasonality that may cause fluctuations in our sales, cash flows and results of operations;
•our
failure to achieve or maintain profitability;
•our revenue not growing at the rates they historically have, or at all;
•our failure to successfully execute on our growth initiatives, business strategies, or operating plans, including growth in our non-BPCI-A episodes of care business;
•our failure to successfully launch new products;
•our failure to diversify sources of revenues and earnings;
•inaccurate estimates and assumptions used to determine the size of our total addressable market;
•changes in accounting principles applicable to us;
•incorrect estimates or judgments relating to our critical accounting policies;
•our failure to effectively adapt to changes in the healthcare industry, including changes in the rules governing Medicare or other federal healthcare programs, or a potential shift toward total cost of care payment models;
•our failure to adhere to complex and evolving governmental laws and regulations;
•our failure to comply with current and future federal and state privacy, security and data protection laws, regulations or standards;
•our employment of and contractual relationships with our providers subjecting us to licensing
or other regulatory risks, including recharacterization of our contracted providers as employees;
•adverse findings from inspections, reviews, audits and investigations from health plans or government agencies;
•inadequate investment in or maintenance of our operating platform and other information technology and business systems;
•our ability to develop and/or enhance information technology systems and platforms to meet our changing customer needs;
•higher than expected investments in our business, including, but not limited to, investments in our technology and operating platform, which could reduce our profitability;
•security
breaches or incidents, loss or misuse of data, a failure in or breach of our operational or security systems or other disruptions;
•disruptions in our disaster recovery systems or management continuity planning;
•our ability to comply with, and changes to, laws, regulations and standards relating to privacy or data protection;
•our ability to obtain, maintain, protect and enforce our intellectual property;
•our dependence on distributions from Cure TopCo, LLC, our operating subsidiary, to fund dividend payments, if any, and to pay our taxes and expenses, including payments under the Tax Receivable Agreement (“TRA”);
•the
control certain equityholders have over us and our status as a controlled company;
•our ability to realize any benefit from our organizational structure;
•risk associated with acquiring other businesses including our ability to effectively integrate the operations and technologies of the acquired businesses, including Caravan Health;
•risks associated with an increase in our indebtedness; and
•the other risk factors described under Part II, Item 1A. Risk Factors and in Part I, Item 1A. Risk Factors of our 2021 Annual Report on Form 10-K.
All forward-looking statements attributable to us or persons acting on our behalf are
expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
Overview
The following discussion of our financial condition and results of operations should be read in conjunction with the Condensed Consolidated Financial Statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical consolidated financial
information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs and that involve risks and uncertainties. Our actual results may differ materially from those discussed in the forward-looking statements as a result of various factors, including those set forth in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and Note Regarding Forward-Looking Statements included in this Quarterly Report on Form 10-Q.
The following discussion contains references to periods prior to the Reorganization Transactions that Signify Health, Inc. (referred to herein as “we”, “our”, “us”, “Signify Health” or the “Company”) and Cure TopCo, LLC (“Cure TopCo”) entered
into in connection with its initial public offering (the “Reorganization Transactions”), which were effective February 12, 2021. Any information related to periods prior to the Reorganization Transactions refer to Cure TopCo and its consolidated subsidiaries and any information related to periods subsequent to the Reorganization Transactions refer to Signify Health and its consolidated subsidiaries, including Cure TopCo.
Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to transform how care is paid for and
delivered so that people can enjoy more healthy, happy days at home. By activating the home as a key part of the care continuum, we are helping lessen dependence on facility-centric care, preventing costly adverse events and facilitating holistic condition management across settings of care. Our customers include health plans, governments, employers, health systems and physician groups. We believe that we are a market leader in two fast-growing segments of the value-based healthcare payment industry: (1) payment models based on individual episodes of care and (2) in-home health evaluations (“IHEs”). Payment models based on individual episodes of care organize, or “bundle”, payments for all, or a substantial portion of, services received by a patient in connection with an episode of care, such as a surgical procedure, particular condition or other reason for a hospital stay. IHEs are health evaluations performed by a clinician in the home to support payors’
participation in Medicare Advantage and other government-run managed care plans. Our episode payment platform managed $4.62 billion and $5.21 billion of spend in 2021 and 2020, respectively. Our mobile network of providers completed evaluations for over 1.9 million individuals participating in Medicare Advantage and other managed care plans in 2021. We believe that these core businesses have enabled us to become integral to how health plans and healthcare providers successfully participate in value-based payment programs, and that our platform lessens the dependence on facility-centric care for acute and post-acute services and shifts more services towards alternate sites and, most importantly, the home.
On March 1, 2022, we acquired Caravan Health, Inc. (“Caravan Health”).
The combination creates one of the largest national networks of providers engaged in value-based payment models providing a broader range of value-based and shared savings models from advanced primary care to specialty care bundles to total cost of care programs. We believe the acquisition of Caravan Health will also position us to better to serve community hospitals, physician practices and clinics – entities that have been slower to adopt episodes of care and bundled payments due to a lack of infrastructure to do so.
Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical,
social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost. Our business model is aligned with our customers, as we generate revenue only when we successfully engage members for our health plan customers and generate savings for our provider customers.
Recent Developments for Quarter ended March 31, 2022 and Factors Affecting Our Results of Operations
Below
is a summary of recent developments and factors that impact results of operations, including comparability to historical results of operations. As a result of a number of factors, our historical results of operations may not be comparable to our results of operations in future periods, and our results of operations may not be directly comparable from period to period. For a complete list of factors affecting our results of operations, refer to our 2021 Annual Report on Form 10-K.
Caravan Health Acquisition
On March 1, 2022, we completed the acquisition of Caravan Health for an initial purchase price of approximately $250.0 million, subject to certain customary adjustments,
and included $190.0 million in cash and $60.0 million in our Class A common stock, comprised of 4,726,134 shares at $12,5993 per share, which represents the volume-weighted average price per share of our common stock for the five trading days ending three business days prior to March 1, 2022. In connection and concurrently with entry into the Merger Agreement, we entered into support agreements with certain shareholders of Caravan Health, pursuant to which such shareholders agreed that, other than according to the terms of its respective support agreement, it will not, subject to certain limited exceptions, transfer, sell or otherwise dispose of any Signify shares for a period of up to five years following closing of the merger. In addition to the initial purchase price, the transaction included contingent additional payments of up to $50.0 million based on certain future performance criteria of Caravan Health, which
if conditions are met, may be paid in the second half of 2023. The fair value of the contingent consideration as of the acquisition date was estimated to be approximately $30.5 million.
As part of the Caravan Health acquisition, we assigned preliminary values to the assets acquired and the liabilities assumed based upon their fair values at the acquisition date. We acquired $93.9 million of intangible assets, consisting primarily of customer relationships of $69.8 million (10-year useful life), acquired technology of $23.4 million (5-year useful life) and a tradename of $0.7 million (3-year useful life), which we also expect will increase our amortization expense in future periods. As a result of the Caravan Health acquisition, we also recorded $199.3 million in goodwill, which represented the amount by which the purchase price exceeded the fair value of the net assets acquired.
Pro
forma results of operations related to this acquisition have not been presented as the acquisition did not meet the prescribed significance tests set forth in Regulation S-X requiring such disclosure. The financial results of Caravan Health have been included in our Condensed Consolidated Financial Statements since the date of the acquisition. Due to the above factors, and in particular the increase in amortization expense, our results of operations for periods subsequent to the acquisition are not directly comparable to our results of operations for the periods prior to the acquisition date.
IHE volume
In the first three months of 2022, we completed and sent to customers approximately
0.56 million IHEs, including vIHEs, compared to 0.46 million IHEs in the first three months of 2021.
COVID-19 Update
Our operations in our Home & Community Services segment were significantly affected by the COVID-19 pandemic early in 2020. However, as the COVID-19 pandemic has evolved, we have been able to pivot and flex the
volume of virtual IHEs
(“vIHEs”) when necessary and as a result we have not experienced a material impact to our results of operation as a result of the ongoing pandemic since the second quarter of 2020.
Our Episodes of Care Services segment has experienced a more prolonged negative impact related to the pandemic. At certain times during the pandemic, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments, including certain acute and post-acute care services, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19. In addition, the temporary suspension or cancellation of services was put in place to focus limited resources and personnel capacity toward the prevention of, and care for patients with, COVID-19. This resulted in fewer elective procedures and
a general reduction in individuals seeking medical care starting at the end of the first quarter of 2020, which contributed to a substantially lower number of episodes being managed in 2020 and 2021. Due to the nature of the BPCI-A program, however, there is a significant lag between when the episodes are initiated and when CMS reconciles those services and we recognize revenue over a 13 month period encompassing both of those points in time. As such, there was no immediate impact to our revenues in early 2020 when the pandemic began. However, the specific impact of the lower volumes on our program size and revenues has resulted in a decline in weighted average program size and savings rates. In addition, in the third quarter of 2020 and in response to the COVID-19 pandemic, CMS announced that episodes with a COVID-19 diagnosis would be excluded from reconciliation irrespective of the impact on the outcome of the episode, and this exclusion has extended into 2022, resulting
in a negative impact to our program size. We would expect this impact on the program size to decrease once the COVID-19 pandemic subsides or CMS removes this rule.
Initially, the reduction in the number of episodes managed was offset by a higher savings rate achieved due to a combination of improved performance by some of our partners as well as certain partners that were underperforming choosing to exclude some or all of their episodes from reconciliation in 2020. However, beginning with the reconciliation results received from CMS during the second quarter of 2021, we saw a negative impact on our savings rate as a result of the COVID-19 pandemic. This result was driven primarily by two factors, including 1) the under-diagnosis of co-morbidities, as a result of the COVID-19 pandemic and individuals skipping annual or routine visits to the doctor’s office, which
led to higher actual costs of treatment without an attendant patient mix adjustment by CMS and therefore reduced our savings rate; and 2) the use of higher cost next site of care facilities as a result of the COVID-19 pandemic driven by reduced availability of skilled nursing facilities as a next site of care option upon hospital discharge. Although the availability of skilled nursing facilities has improved, patients continue to be discharged to inpatient rehabilitation facilities and other high-cost next sites of care, which reduces our savings rate.
Due to the passage of time between when we perform our services and the confirmation of results and subsequent cash settlement by CMS, COVID-19 and the aforementioned negative impacts have also negatively impacted our semi-annual cash flows related to the BPCI-A program.
Because
our administrative fee is calculated as a percentage of program size and we receive a portion of the savings achieved in management of an episode, the decrease in episodes and related reduction in overall program size have had, and we expect will continue to have, a negative effect on our revenue. Some of these measures and challenges will likely continue for the duration of the COVID-19 pandemic and will harm the results of operations, liquidity and financial condition of our provider partners and our business. Lastly, our representatives may be prohibited from entering hospitals, skilled nursing facilities and other post-acute facilities as a result of the pandemic, which affects our ability to manage post-acute care and could have a material impact on the savings rate being generated by the program.
We continue to monitor trends related to COVID-19, including the recent fluctuations in rates due to variants, changes in CDC recommendations and their impact on results of operations and financial condition on both of our segments.
Equity-based compensation expense
On March 1, 2022, our Board of Directors approved amendments to certain outstanding equity award agreements, subject to performance-based vesting criteria. The equity awards were amended with an effective date of March 7, 2022, and include
3,572,469 outstanding LLC Incentive Units and 817,081 outstanding stock options. The amendments added an alternative two-year service-vesting condition to the performance-vesting criteria, which, through the effective date of the amendment, were considered not probable of occurring and therefore we had not previously recorded any expense related to these awards. The amended equity awards will now be vest based on the satisfaction of the earlier to occur of 1) a two year service condition, with 50% vesting in each of March 2023 and March 2024 or 2) the achievement of the original performance vesting criteria. As a result of this amendment, which results in vesting that is considered probable of occurring, we began to record equity-based compensation expense for these amended equity awards in March 2022. The equity-based compensation expense related to these amended awards is based on the fair value as of the effective date of the amended equity awards and will be recorded
over the two year service period.
The total fair value on March 7, 2022, the amendment effective date, based on a Black-Scholes value of $8.49, for the March 2022 amended stock options as described above was $6.9 million, of which we recorded $0.2 million during the three months ended March 31, 2022. Subsequent to these amendments, there are no longer any stock options outstanding that are subject only to performance-based vesting conditions that are not probable of occurring.
The total fair value on the amendment date for the March 2022 amended LLC Incentive Units was based on the closing stock price on the amendment date of $14.19, resulting in total fair value of $50.7 million, of which we recorded
$1.7 million in equity-based compensation expense during the three months ended March 31, 2022. Subsequent to these amendments, there are 2,202,628 LLC Incentive Units that remain outstanding that are subject only to performance-based vesting conditions that are not probable of occurring.
Additionally, in March 2022, the Board of Directors and the Compensation Committee approved an annual long-term incentive plan equity grant (the “2022 Annual LTIP Equity Grant”) to certain employees. A total of 2,677,979 restricted stock units and 4,059,520 stock options with an exercise price of $14.19 were granted as part of this 2022 Annual LTIP Equity Grant. All awards granted as part of the 2022 Annual LTIP Equity Grant are subject to a four year time vesting schedule. Total grant date fair value related to the 2022 Annual LTIP Equity Grant
was $68.8 million and will be recorded as equity-based compensation expense over the four year service period beginning in March 2022.
As a result of the March 2022 amendments to equity awards with performance-based vesting criteria and the 2022 Annual LTIP Equity Grant, our total equity-based compensation expense is expected to be significantly higher in 2022 and beyond as compared to historical periods.
Adoption of new accounting pronouncement - Leases
In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842) which requires lessees to recognize leases on the balance sheet by
recording a right-of-use asset and lease liability. We adopted this new guidance as of January 1, 2022 and applied the transition option, whereby prior comparative periods will not be retrospectively presented in the consolidated financial statements. We elected the package of practical expedients not to reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs and the lessee
practical expedient
to combine lease and non-lease components for all asset classes. We made a policy election to not recognize right-of-use assets and lease liabilities for short-term leases for all asset classes.See Note 8 Leases to our Condensed Consolidated Financial Statements covered under Part I, Item 1 of this Quarterly Report on Form 10-Q for further details.
Upon adoption on January 1, 2022, we recognized right-of-use assets and lease liabilities for operating leases of $23.0 million and $35.6 million, respectively. The difference between the right-of-use asset and lease liability primarily represents the net book value of deferred rent and tenant improvement allowances recognized as of December
31, 2021, which was adjusted against the right-of-use asset upon adoption.
Non-controlling interest
The non-controlling interest ownership percentage changes as new shares are issued and LLC units are exchanged. During the three months ended March 31, 2022, the change in the non-controlling interest percentage was primarily driven by the shares issued in connection with the Caravan Health acquisition. As of March 31, 2022, we hold approximately 75.5% of Cure TopCo’s outstanding LLC Units and the remaining LLC Units of Cure TopCo are held by the Continuing Pre-IPO LLC Members.
Components of our results of operations
Components of results of operations including revenue, operating expenses and other expense, net are described in our 2021 Annual Report on Form 10-K. Below is an update to the components of results of operations.
Revenue
We have entered into EAR agreements and a separate letter agreement (the “EAR Letter Agreement”) with one of our customers in our Home & Community Services segment. Revenue generated under the underlying customer contracts
includes an estimated reduction in the transaction price for IHEs associated with the initial grant date fair value of the outstanding customer EAR agreements and EAR Letter Agreement. The total grant date fair value of the outstanding EAR agreements was $51.8 million and is being recorded against revenue over their respective performance periods, both of which end in December 2022. The grant date fair value of the EAR Letter Agreement was estimated to be $76.2 million and will be recorded as a reduction of revenue through June 30, 2026, coinciding with the service period as follows: $6.3 million in 2022, $20.0 million in 2023, $20.0 million in 2024, $19.9 million in 2025 and $10.0 million in 2026. See “—Liquidity and capital resources—Customer Equity Appreciation Rights Agreements.”
Caravan
Health enters into contracts with customers to provide multiple services around the management of the ACO model. These include, among others, population health software, analytics, practice improvement, compliance, marketing, governance, surveys and licensing. The overall objective of the services provided is to help the customer receive shared savings from CMS. Caravan Health enters into arrangements with customers wherein we receive a contracted percentage of each customer’s portion of shared savings if earned. We recognize shared savings revenue as performance obligations are satisfied over time, commensurate with the recurring ACO services provided to the customer over a 12-month calendar year period. The shared savings transaction price is variable, and therefore, we estimate an amount we expect to receive for each 12-month calendar year performance obligation period.
In
order to estimate this variable consideration, management initially uses estimates of historical performance of the ACOs. We consider inputs such as attributed patients, expenditures, benchmarks and inflation factors. We adjust our estimates at the end of each reporting period to the extent new information indicates a change is
warranted. We apply a constraint to the variable consideration estimate in circumstances where we believe the data received is incomplete or inconsistent, so as not to have the estimates result in a significant revenue reversal in future periods. Although our estimates
are based on the information available to us at each reporting date, new and material information may cause actual revenue earned to differ from the estimates recorded each period. These include, among others, Hierarchical Conditional Category (“HCC”) coding information,quarterly reports from CMS, unexpected changes in attributed patients and other limitations of the program beyond our control. We receive final reconciliations from CMS and collect the cash related to shared savings earned annually in the third or fourth quarter of each year for the preceding calendar year.
The remaining sources of Caravan Health revenue in our Episodes of Care Services segment are recognized over time when, or as, the performance obligations are satisfied and are primarily based on a fixed fee or per member per month fee. Therefore, they do not
require significant estimates and assumptions by management.
See “—Critical accounting policies—Revenue recognition.”
Results of operations
The following is a discussion of our consolidated results of operations for the three months ended March 31, 2022 and 2021. A discussion of the results by each of our two operating segments, Home & Community Services and Episodes of Care Services, follows the discussion of our consolidated results.
The following table summarizes our results of operations for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
% Change
2022
2021
2022
v. 2021
(in millions)
Revenue
$
216.5
$
180.0
20.3
%
Operating expenses:
Service expense
114.5
98.5
16.3
%
Selling,
general and administrative expense
70.3
57.3
22.9
%
Transaction-related expense
3.2
5.6
(43.4)
%
Depreciation
and amortization
18.0
16.7
7.5
%
Total operating expenses
206.0
178.1
15.7
%
Income from operations
10.5
1.9
NM
Interest
expense
4.0
6.8
(40.7)
%
Other expense (income)
28.8
56.7
(49.2)
%
Other
expense, net
32.8
63.5
(48.3)
%
Loss before income taxes
(22.3)
(61.6)
(63.7)
%
Income tax benefit
(6.0)
(9.9)
(39.2)
%
Net
loss
(16.3)
(51.7)
(68.4)
%
Net loss attributable to pre-Reorganization period
Our total revenue
was $216.5 million for the three months ended March 31, 2022, representing an increase of $36.5 million, or 20.3%, from $180.0 million for the three months ended March 31, 2021. This increase was primarily driven by a $34.5 million increase in revenue from our Home & Community Services segment as well as a $2.0 million increase in revenue from our Episodes of Care Services segment. See “—Segment results” below.
Operating expenses
Our total operating expenses were $206.0 million for the three months ended March 31, 2022, representing an increase of $27.9 million, or 15.7%, from $178.1 million for the
three months ended March 31, 2021. This increase was driven by the following:
•Service expense - Our total service expense was $114.5 million for the three months ended March 31, 2022, representing an increase of $16.0 million, or 16.3%, from $98.5 million for the three months ended March 31, 2021. This increase was primarily driven by expenses related to our network of providers, which increased by $9.3 million, driven by the higher IHE volume and a return to a more traditional mix of in-person IHEs compared to vIHEs. In 2021, primarily as a result of COVID-19, a higher proportion of evaluations were performed as vIHE, which have a lower cost per evaluation. Compensation-related
expenses increased by $6.4 million primarily driven by additional headcount including the incremental employees retained as part of the Caravan Health acquisition and higher benefits expense. Additionally, there was an increase of $1.4 million in other expenses during the three months ended March 31, 2022, primarily driven by the overall higher IHE volume. The impact of COVID-19 was less in 2022, resulting in a decrease of approximately $1.1 million in pandemic-related expenses during the first quarter of 2022 as compared to the first quarter of 2021, including lower costs related to COVID-19 tests for our providers and lower costs for personal protective equipment used by our providers while conducting IHEs during the pandemic.
•Selling, general and administrative (“SG&A”) expense - Our
total SG&A expense was $70.3 million for the three months ended March 31, 2022, representing an increase of $13.0 million, or 22.9%, from $57.3 million for the three months ended March 31, 2021. This increase was primarily driven by compensation-related expenses, which increased by $7.3 million due to additional headcount to support the overall growth in our business including the incremental employees retained as part of the Caravan Health acquisition and higher benefits costs. Other costs also increased, including an increase of $1.7 million in bad debt expense, an increase of $1.7 million in information technology-related expenses, including infrastructure and software costs, an increase of $1.2 million in other variable costs and an increase of $1.1 million in employee travel and entertainment expenses as COVID-19 imposed travel restrictions eased.
•Transaction-related
expenses - Our total transaction-related expenses were $3.2 million for the three months ended March 31, 2022, representing a decrease of $2.4 million, or 43.4%, from $5.6 million for the three months ended March 31, 2021. In 2022, the transaction-related expenses consisted primarily of consulting and other professional services expenses incurred in connection with general corporate development activities, including the Caravan Health acquisition and other potential acquisitions that did not proceed. In addition, transaction-related expenses in 2022 included certain integration-related expenses, including compensation expenses and consulting and other professional services expenses, following the Caravan Health acquisition. In 2021, the transaction-related expenses consisted primarily of consulting and other professional services expenses, as well
as compensation expenses, incurred in connection with our IPO and general corporate development activities, including potential acquisitions that did not proceed.
•Depreciation and amortization - Our total depreciation and amortization expense was $18.0 million for the three months ended March 31, 2022, representing an increase of $1.3 million, or 7.5%, from $16.7 million for the three months ended March 31, 2021.
This increase in depreciation and amortization expense was primarily driven by a net increase in amortization expense of $1.1 million, primarily due to additional capital expenditures related to internally-developed software over the past year and the $93.9 million in intangible assets acquired in connection with the Caravan Health acquisition in March 2022, partially offset by certain intangible assets becoming fully amortized in 2021. Additionally, there was an increase in depreciation expense of $0.2 million, primarily driven by additional capital expenditures over the past year.
Other expense, net
Other expense, net was $32.8 million for the three months ended March 31, 2022, representing a decrease of $30.7 million from $63.5 million for the
three months ended March 31, 2021. This decrease was primarily driven by the remeasurement of the fair value of the outstanding customer EAR liabilities, which resulted in expense of $28.9 million for three months ended March 31, 2022, representing a decrease of $27.9 million from expense of $56.8 million for the three months ended March 31, 2021. Interest expense also decreased by $2.8 million primarily driven by the lower outstanding principal balance and lower interest rates following our June 2021 refinancing of the 2021 Credit Agreement.
Income tax benefit
Income tax benefit was $6.0 million for the three months ended March
31, 2022, representing a decrease of $3.9 million from $9.9 million for the three months ended March 31, 2021. The effective tax rate for the three months ended March 31, 2022 was 27.0% compared to 16.1% for the three months ended March 31, 2021. The effective tax rate in 2022 is higher than the statutory federal and state income tax rate of approximately 25% primarily due to unrealizable net operating losses which require a valuation allowance and the impact of the non-controlling interest partially offset by a tax benefit associated with stock option exercises.
Segment results
We evaluate the performance of each of our two operating segments based
on segment revenue and segment adjusted EBITDA. Service expense for each segment is based on direct expenses associated with the revenue generating activities of each segment. We allocate SG&A expenses to each segment primarily based on the relative proportion of direct employees.
The following table summarizes our segment revenue, segment adjusted EBITDA and the percentage of total consolidated revenue and consolidated adjusted EBITDA, respectively, for the periods presented:
Three
months ended March 31,
% Change
2022
% of Total
2021
% of Total
2022 v 2021
(in millions)
Revenue
Home
& Community Services
Evaluations
$
186.2
86.0
%
$
150.3
83.5
%
23.9
%
Other
0.7
0.3
%
2.1
1.2
%
(66.9)
%
Total
Home & Community Services revenue
186.9
86.3
%
152.4
84.7
%
22.6
%
Episodes of Care Services
Episodes
24.1
11.1
%
25.4
14.0
%
(5.2)
%
Other
5.5
2.6
%
2.2
1.3
%
153.8
%
Total
Episodes of Care Services revenue
29.6
13.7
%
27.6
15.3
%
7.3
%
Segment Adjusted EBITDA
Home
& Community Services
55.9
124.3
%
41.1
119.4
%
35.8
%
Episodes of Care Services
(10.9)
(24.3)
%
(6.7)
(19.4)
%
(63.0)
%
Home
& Community Services revenue was $186.9 million for the three months ended March 31, 2022, representing an increase of $34.5 million, or 22.6%, from $152.4 million for the three months ended March 31, 2021. This increase was primarily driven by Evaluations revenue, which increased by $35.9 million. The higher Evaluations revenue was driven by increased IHE volume and a reduction in the proportion of IHEs conducted as vIHEs, which are performed at a lower price per evaluation compared to in-person IHEs. Evaluations revenue included a reduction associated with the grant date fair value of the outstanding customer EARs and EAR Letter Agreement of $6.5 million and $4.9 million during the three months ended March 31, 2022 and 2021, respectively. Other revenue decreased by
$1.4 million, primarily due to a decrease in revenue from our biopharmaceutical services and standalone sales of our social determinants of health product.
Episodes of Care Services revenue was $29.6 million for the three months ended March 31, 2022, representing an increase of $2.0 million, or 7.3%, from $27.6 million for the three months ended March 31, 2021. This increase was primarily driven by the Caravan Health acquisition, which contributed $— million in revenue for the three months ended March 31, 2022. This increase was partially offset by a decrease of $1.3 million in Episodes revenue due to the adverse effects of COVID-19 on program size and savings rate, including lower healthcare utilization, the exclusion of episodes of care
with a COVID-19 diagnosis and the impact of the patient case mix adjustment and inpatient rehabilitation center utilization on savings rate. Other revenue increased $3.3 million in 2022 primarily driven by Caravan Health acquisition.
Home & Community Services Adjusted EBITDA was $55.9 million for the three months ended March 31, 2022, representing an increase of $14.8 million, or 35.8%, from $41.1 million for the three months ended March 31, 2021. This increase was primarily driven by the increase in revenue described above partially offset by higher operating expenses as a result of the variable costs associated with increased volume and the investments to support our growth and technology.
Episodes
of Care Services Adjusted EBITDA was a loss of $10.9 million for the three months ended March 31, 2022, representing an increase of $4.3 million, or 63.0%, from a loss of $6.7 million for the three months ended
March 31, 2021. This increase in the loss was primarily driven by the lower Episodes revenue described above and higher operating expenses as a result of investments to support our future growth and technology.
Liquidity
and capital resources
Liquidity describes our ability to generate sufficient cash flows to meet the cash requirements of our business operations, including working capital needs to meet operating expenses, debt service, acquisitions when pursued and other commitments and contractual obligations. We consider liquidity in terms of cash flows from operations and their sufficiency to fund our operating and investing activities.
Our primary sources of liquidity are our existing cash and cash equivalents, cash provided by operating activities and borrowings under our Credit Agreement, including borrowing capacity under our Revolving Facility (as defined below). As of March 31, 2022, we had unrestricted cash and cash equivalents of $451.3 million. Our total
indebtedness was $348.3 million as of March 31, 2022.
In June 2021, we entered into a credit agreement with a secured lender syndicate (the “2021 Credit Agreement”). The 2021 Credit Agreement includes a term loan of $350.0 million (the “2021 Term Loan”) and a revolving credit facility (the “Revolving Facility”) with a $185.0 million borrowing capacity. See Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operation —Liquidity and capital resources —Indebtedness” in our 2021 Annual Report on Form 10-K. As of March 31, 2022, we had available borrowing capacity under the Revolving Facility of $172.8 million, as the borrowing capacity is reduced by outstanding letters of credit of $12.2 million.
Our
principal liquidity needs are working capital and general corporate expenses, debt service, capital expenditures, obligations under the Tax Receivable Agreement, income taxes, acquisitions when pursued and other investments to help achieve our growth strategy. In March 2022, we acquired Caravan Health, using approximately $189.6 million in cash, net of the cash acquired from Caravan Health. In addition, we issued approximately $60.0 million in our Class A common stock, comprised of 4,726,134 shares at $12.5993 per share, which represents the volume-weighted average price per share of our common stock for the five trading days ending three business days prior to March 1, 2022.
Our capital expenditures for property and equipment to support growth in the business were $1.7 million and $0.7 million for the three months ended March
31, 2022 and 2021, respectively.
Our liquidity may fluctuate on a quarterly basis due to our agreements with CMS under the BPCI-A program. Cash receipts generated under these contracts, which represents the majority of revenue in our Episodes of Care Services segment, are subject to a semiannual reconciliation cycle, which occurs in the second and fourth quarters of each year. We typically receive cash receipts under these contracts in the quarter subsequent to the receipt of the reconciliation, or during the first and third quarters of each year, which can cause our liquidity position to fluctuate from quarter to quarter. In addition, Caravan Health’s
participation in the CMS MSSP ACO program will also result in fluctuations in liquidity from period to period, as this is a calendar year program, with annual shared savings reconciled and distributed approximately nine months after the calendar year program ends. For example, we would expect shared savings receipts in the third or fourth quarter of 2022 related to the 2021 ACO plan year.
Our Home & Community Services segment generally experiences seasonality patterns in IHE volume as described in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations —Factors affecting our results of operations” in our 2021 Annual Report on Form 10-K. We did experience a high IHE volume during the three months ended March 31, 2022 and expect a historical seasonality trend to occur during 2022, thus creating
a seasonality effect on liquidity. Additionally, liquidity in our Home &
Community Services segment was impacted by delayed collections during the first quarter of 2022 from certain clients where we are experiencing significant expansion, which we believe is temporary in nature.
In our Episodes of Care Services segment, the ongoing negative effects of the COVID-19 pandemic and CMS’ response to the pandemic, have impacted the semi-annual reconciliations we receive and the subsequent cash receipts since late 2020. We
expect to receive lower cash payments from CMS for reconciliations received in 2022 as compared to the reconciliations received prior to the pandemic. See “—COVID-19 Update” Additionally, in 2021, CMS announced a change to the period in which they will pay funds related to expirations. This change will result in a delayed payment for one period, which had a temporary adverse impact on the cash received in the first quarter of 2022 following the receipt of our semi-annual reconciliation during the fourth quarter of 2021.
In the first quarter of 2022, we announced we are developing a technology center in Galway, Ireland where we intend to employ software engineers and other employees to support our operations in the United States. This will be our first international expansion, which will require capital funding and expose us to currency risk.
We
believe that our cash flow from operations, capacity under our Revolving Facility and available cash and cash equivalents on hand will be sufficient to meet our liquidity needs for at least the next 12 months. We anticipate that to the extent that we require additional liquidity, it will be funded through the incurrence of additional indebtedness, the issuance of additional equity, or a combination thereof. We cannot assure you that we will be able to obtain this additional liquidity on reasonable terms, or at all. Additionally, our liquidity and our ability to meet our obligations and fund our capital requirements are also dependent on our future financial performance, which is subject to general economic, financial and other factors that are beyond our control. See “—Item 1A. Risk factors.” Accordingly, we cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available from additional indebtedness
or otherwise to meet our liquidity needs. If we decide to pursue one or more significant acquisitions, we may incur additional debt or sell or issue additional equity to finance such acquisitions, which could possibly result in additional expenses or dilution.
Comparative cash flows
The following table sets forth our cash flows for the periods indicated:
Net cash (used in) / provided by operating activities/
$
(32.3)
$
86.7
Net cash used in investing activities
(198.4)
(6.4)
Net
cash provided by financing activities
0.1
603.6
Net (decrease) / increase in cash, cash equivalents and restricted cash
(230.6)
683.9
Cash, cash equivalents and restricted cash - beginning of year
684.2
77.0
Cash, cash equivalents and restricted
cash - end of period
$
453.6
$
760.9
Operating activities
Net cash used in operating activities was $32.3 million in 2022, a decrease of $119.0 million, compared to net cash provided by operating activities of $86.7 million in 2021.
Net loss was $16.3 million in 2022, as compared to a net loss of $51.7 million in 2021. The decrease in net loss was primarily due to revenue growth partially offset by an increase in operating expenses. Non-cash items were $49.5 million in 2022 as compared to $67.8 million in 2021. The decrease in non-cash net expense items included in net income was primarily driven by the lower expense related to the remeasurement of customer equity appreciation rights driven by changes in relative value of our stock price in 2022 compared to 2021.
Changes in operating assets and liabilities resulted in a cash decrease of $65.5 million in 2022, as compared to a cash increase of $70.6 million in 2021. The change in operating assets and liabilities was primarily driven by a net increase in accounts receivable of $1.9 million in 2022
compared to a net decrease in accounts receivable of $101.2 million in 2021. Accounts receivable for our Home & Community Services segment increased $63.8 million in 2022 compared to a $13.7 million increase in 2021. The increase in accounts receivable in 2022 was primarily driven by higher IHE volume in 2022 and the impact of temporarily delayed collections for certain Home & Community Services customers during the first quarter of 2022. Accounts receivable for our Episodes of Care Services segment decreased $60.3 million in 2022 compared to $114.9 million in 2021. The decrease in cash receipts in the Episodes of Care Services segment in 2022 as compared to 2021 was primarily driven by the impact of COVID-19, which has led to a reduction in program size and the CMS imposed one time-delayed cash related to expirations, as the cash receipt shifted to being paid one performance period in arrears.
The
net impact of changes in contract assets and liabilities during 2022 was a $28.0 million reduction in cash as compared to an $18.9 million decrease in cash in 2021. The increase in net contract assets in 2022 was primarily driven by changes in the estimate of variable consideration in our Episodes of Care Services segment including variable consideration generated by Caravan Health. An increase in operating expenses as a result of the investments to support our growth and technology has further impacted our working capital needs.
Accounts receivable, contract assets and contract
liabilities fluctuate from period to period as a result of periodically slower client collections and the results of the semi-annual reconciliations in our Episodes of Care Services segment.
Investing activities
Net cash used in investing activities was $198.4 million in 2022, an increase of $192.0 million, compared to net cash used in investing activities of $6.4 million in 2021. The primary use of cash from investing activities in 2022 was the initial cash consideration, net of cash acquired, for the Caravan Health acquisition of $189.6 million. Capital expenditures for property and equipment were $1.7 million in 2022 compared to $0.7 million in 2021. The $1.0 million increase in capital expenditures for property and equipment was primarily driven by computer equipment purchases. Capital expenditures for internal-use software
development were $6.8 million in 2022 compared to $5.7 million in 2021. The $1.1 million increase in capital expenditures for internal-use software development was primarily driven by additional investments in our technology platforms to support future growth. Investing activities also included a $0.3 million equity investment in AloeCare Health in 2022.
Financing activities
Net cash provided by financing activities was $0.1 million in 2022, a decrease of $603.5 million, compared to net cash provided by financing activities of $603.6 million in 2021. The primary source of cash from financing activities in 2022 was proceeds of $1.6 million related to the issuance of common stock in connection with the exercise of stock options partially offset by scheduled principal payments under our 2021 Credit Agreement of $0.9 million
and $0.3 million in tax distributions on behalf of the non-controlling interest. The primary source of cash
from financing activities in 2021 was $604.8 million in net proceeds from our IPO partially offset by scheduled principal payments on long-term debt of $1.0 million.
In
each of December 2019 and September 2020, we entered into EAR agreements with one of our customers. Pursuant to the agreements, certain revenue targets were established for the customer to meet in the next three years. If they meet those targets, they retain the EAR. If they do not meet such targets, they forfeit all or a portion of the EAR. Each EAR agreement allows the customer to participate in the future growth in the fair market value of our equity and can only be settled in cash (or, under certain circumstances, in whole or in part with a replacement agreement containing substantially similar economic terms as the original EAR agreement) upon a change-in-control of us, other liquidity event, or upon approval of our Board of Directors with the consent of New Mountain Capital subject to certain terms and conditions. Each EAR will expire 20 years from the date of grant, if not previously settled.
Pursuant
to the terms of the EAR agreements, the value of the EARs will be calculated as an amount equal to the non-forfeited portion of a defined percentage (3.5% in the case of the December 2019 EAR and 4.5% in the case of the September 2020 EAR) of the excess of (i) the aggregate fair market value of the Reference Equity (as defined below) as of the applicable date of determination over (ii) a base threshold equity value defined in each agreement. Pursuant to the terms of each agreement, the “Reference Equity” is the Class A common stock of the Company and the aggregate fair market value of the Reference Equity will be determined by reference to the volume-weighted average trading price of the Company’s Class A common stock (assuming all of the holders of LLC Units redeemed or exchanged their LLC
Units for a corresponding number of newly issued shares of Class A common stock) over a period of 30 calendar days. In addition, following the IPO, the base threshold equity value set forth in each agreement was increased by the aggregate offering price of the IPO.
On December 31, 2021, we entered into an amendment of the December 2019 EAR and the September 2020 EAR (collectively, the “EAR Amendments”). The EAR Amendments provide, among other things, that the customer may exercise any unexercised, vested and non-forfeited portion of each EAR upon the sale of our Class A common stock by New Mountain Capital, our sponsor, subject to certain terms and conditions. These terms and conditions include, among others, that the customer has met its revenue targets under each EAR for 2022 and that New Mountain Capital has sold our Class
A common stock above a certain threshold as set forth in each amendment. We have the option to settle any portion of the EARs so exercised in cash or in Class A common stock, provided that the aggregate amount of any cash payments do not exceed $25.0 million in any calendar quarter (with any amounts exceeding $25.0 million to be paid in the following quarter or quarters).
We and our customer also agreed to extend our existing commercial arrangements through the middle of 2026 and established targets for the minimum number of IHEs to be performed on behalf of the customer each year (the “Volume Targets”). The EAR Amendments did not result in any incremental expense as the fair value at the time of modification did not exceed the fair value of the original December 2019 EAR and September 2020 EAR immediately prior to the modification. Accordingly, we will continue to recognize the original
grant date fair value of the 2019 EAR and 2020 EAR awards as a reduction to revenue.
We also entered into the EAR Letter Agreement with the customer that provides that, in the event of a change in control of the Company or certain other corporate transactions, and subject to achievement of the Volume Targets, if the aggregate amount paid under the EARs prior to and in connection with such event (the “Aggregate EAR Value”) is less than $118.5 million, then the customer will be paid the difference between $118.5 million and the Aggregate EAR Value. The EAR Letter Agreement is a separate equity-linked instrument. The EAR Letter Agreement was determined to be a separate equity instrument, independent from the original EARs, as amended.
The grant date fair value is determined based on an option pricing model. Similar to the original EARs, we will record the initial grant date fair value as a reduction to revenue over the performance period. Estimated changes in fair market value will be recorded each accounting period based on management’s current assumptions related to the underlying valuation approaches as other (income) expense, net on the Condensed Consolidated Statement of Operations. The grant date fair value of the EAR Letter Agreement was estimated to be $76.2 million and will be recorded as a reduction of revenue through June 30, 2026, coinciding with the service period. The EAR Letter Agreement was executed on December 31, 2021 and, therefore, there was no material impact on our results of operations in 2021.
As
of March 31, 2022, cash settlement of the EARs was expected to be a minimum of $118.5 million but was not considered probable, due to the change in control and liquidity provisions of each EAR. The grant date fair value of the December 2019 EAR was estimated to be $15.2 million and is being recorded as a reduction of revenue through December 31, 2022, coinciding with the three-year performance period. The grant date fair value of the September 2020 EAR was estimated to be $36.6 million and is being recorded as a reduction of revenue through December 31, 2022, coinciding with the 2.5-year performance period. As of March 31, 2022, the total combined estimated fair market value of the EARs, as amended, and EAR Letter Agreement was approximately $175.5 million.
Non-GAAP
financial measures
Adjusted EBITDA and Adjusted EBITDA Margin are not measures of financial performance under GAAP and should not be considered substitutes for GAAP measures, including net income or loss, which we consider to be the most directly comparable GAAP measure. Adjusted EBITDA and Adjusted EBITDA Margin have limitations as analytical tools, and when assessing our operating performance, you should not consider these non-GAAP financial measures in isolation or as substitutes for net income or loss or other consolidated income statement data prepared in accordance with GAAP. Other companies may calculate Adjusted EBITDA and Adjusted EBITDA Margin differently than we do, limiting its usefulness as a comparative measure.
We define Adjusted EBITDA as net income (loss) before interest expense, loss on extinguishment
of debt, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net, transaction-related expenses, equity-based compensation, remeasurement of contingent consideration, SEU expense and non-recurring expenses. We believe that Adjusted EBITDA provides a useful measure to investors to assess our operating performance because it eliminates the impact of expenses that do not relate to ongoing business performance, and that the presentation of this measure enhances an investor’s understanding of the performance of our business.
Adjusted EBITDA is a key metric used by management and our Board of Directors to assess the performance of our business. We believe that Adjusted EBITDA provides a useful measure to investors to assess our operating performance because it eliminates the impact of expenses that do
not relate to ongoing business performance, and that the presentation of this measure enhances an investor’s understanding of the performance of our business. We believe that Adjusted EBITDA Margin is helpful to investors in measuring the profitability of our operations on a consolidated level.
Our use of the terms Adjusted EBITDA and Adjusted EBITDA Margin may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA and Adjusted EBITDA Margin have important limitations as analytical tools. For example, Adjusted EBITDA and Adjusted EBITDA Margin:
•do not reflect any cash capital expenditure requirements for the assets being depreciated and amortized that may have to be replaced in the future;
•do not reflect changes in, or cash requirements for, our working capital needs;
•do not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our core operations;
•do not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our debt; and
•do not reflect equity-based compensation expense and other non-cash charges; and exclude certain tax payments that may
represent a reduction in cash available to us.
Adjusted EBITDA increased by $10.6 million, or 30.5%, to $45.0 million for the three months ended March 31, 2022 from $34.4 million for the three months ended March 31, 2021.
We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. We believe that Adjusted EBITDA Margin is helpful to investors in measuring the profitability of our operations on a consolidated basis. Adjusted EBITDA Margin increased by approximately 170 basis points to 20.8% for the three months ended March 31, 2022 from 19.1% for the three months ended March 31, 2021.
The
following table shows a reconciliation of net income (loss) to Adjusted EBITDA for the periods presented:
(a)Represents
other non-operating (income) expense that consists primarily of the quarterly remeasurement of fair value of the outstanding customer EARs and EAR Letter Agreement as well as interest and dividends earned on cash and cash equivalents.
(b)Represents transaction-related expenses that consist primarily of expenses incurred in connection with acquisitions and other corporate development activities, including the Caravan Health acquisition and potential mergers and acquisitions activity that did not proceed, strategic investments and similar activities.
Expenses
incurred in connection with our IPO, which cannot be netted against proceeds, are also included in transaction-related expenses in 2021.
(c)Represents expense related to equity incentive awards, including incentive units, stock options and RSUs, granted to certain employees, officers and non-employee directors as long-term incentive compensation. We recognize the related expense for these awards ratably over the vesting period or as achievement of performance criteria become probable.
(d)Represents the reduction of revenue related to the grant date fair value of the customer EARs granted pursuant to the customer EAR agreements we entered into in December 2019 and September 2020, as amended and the EAR Letter Agreement we entered into in December 2021.
(e) Represents remeasurement of contingent consideration in 2022 related to potential payments due upon completion of certain performance targets in connection with the Caravan Health acquisition.
(f)Represents compensation expense related to awards of SEUs subject to time-based vesting. A limited number of SEUs were granted in 2020 and 2021 at the time of the IPO; no future grants of SEUs will be made. Compensation expense related to these awards is tied to the 30-trading day average price of our Class A common stock, and therefore is subject to volatility and may fluctuate from period to period until settlement occurs.
(g)Represents certain gains and expenses incurred that are not expected to recur, including those associated with the closure of certain facilities
and the early termination of certain contracts as well as one-time expenses associated with the COVID-19 pandemic.
Contractual Obligations and Commitments
Our material cash requirements include non-cancelable purchase commitments, lease obligations, debt and debt service, payments under the TRA and settlement of the outstanding customer EARs, among others. As of March 31, 2022, there have been no material changes from the contractual obligations and commitments previously disclosed in our 2021 Annual Report on Form 10-K other than as described below.
Effective
April 1, 2022, we entered into a new lease agreement for a facility in Galway, Ireland. The lease term is 15 years with an option to terminate after 10 years, and total lease payments are expected to be approximately $7.0 million over 10 years, or $11.1 million over 15 years.
Off-balance sheet arrangements
Except for certain letters of credit entered into in the normal course of business and the unconsolidated VIEs related to Caravan Health as described in the condensed consolidated financial statements, we do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition,
revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Critical accounting policies
The discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our financial statements requires us to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses and related disclosures of contingent assets and liabilities. We base these estimates on our historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual
results experienced may vary materially and adversely from our estimates. Revisions to estimates are recognized prospectively. There have been no material changes, other than as described below, to our
critical accounting policies and estimates as compared to the critical accounting policies and estimates described under Part II, Item 7. “Management's Discussion and Analysis of Financial Condition and Results of Operations” of our 2021 Annual Report on Form 10-K.
Revenue
recognition
There have been no material changes to our revenue recognition critical accounting policies and estimates, other than as described below related to the acquisition of Caravan Health. We recognize revenue as the control of promised services is transferred to our customers and we generate all of our revenue from contracts with customers. The amount of revenue recognized reflects the consideration to which we expect to be entitled in exchange for these services. The measurement and recognition of revenue requires us to make certain judgments and estimates.
We apply the five-step model to recognize revenue from customer contracts.
The five-step model requires us to (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when, or as, we satisfy the performance obligation.
The unit of measure for revenue recognition is a performance obligation, which is a promise in a contract
to transfer a distinct or series of distinct goods or services to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
Our customer contracts have either (1) a single performance obligation as the promise to transfer services is not separately identifiable from other promises in the contracts and is, therefore, not distinct; (2) a series of distinct performance obligations; or (3) multiple performance obligations, most commonly due to the contract
covering multiple service offerings. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation on the basis of the relative standalone selling price of each distinct service in the contract.
Episodes of Care Services
Caravan Health enters into contracts with customers to provide multiple services around the management of the ACO model. These include, but are not limited to, population
health software, analytics, practice improvement, compliance, marketing, governance, surveys and licensing. The overall objective of the services provided is to help the customer receive shared savings from CMS. Caravan Health enters into arrangements with customers wherein we receive a contracted percentage of each customer’s portion of shared savings if earned. We recognize shared savings revenue as performance obligations are satisfied over time, commensurate with the recurring ACO services provided to the customer over a 12-month calendar year period. The shared savings transaction price is variable, and therefore, we estimate an amount in which we expect to be entitled to receive for each 12-month calendar year performance obligation period.
In order to estimate this variable consideration, management initially uses estimates of historical performance of the ACOs. We consider inputs
such as attributed patients, expenditures, benchmarks and inflation factors. We adjust our estimates at the end of each reporting period to the extent new information indicates a change is needed. We apply a constraint to the variable consideration estimate in circumstances where we believe the data received is incomplete or inconsistent, so as not to have the estimates result in a significant revenue reversal in future periods. Although our estimates are based on the information available to us at each reporting date, new and material information may cause actual revenue earned to differ from the estimates recorded each period. These include,
among
others, HCC coding information,quarterly reports from CMS, unexpected changes in attributed patients and other limitations of the program beyond our control. We receive final reconciliations from CMS and collect the cash related to shared savings earned annually in the third or fourth quarter of each year for the preceding calendar year.
The remaining sources of Caravan Health revenue in our Episodes of Care Services segment are recognized over time when, or as, the performance obligations are satisfied and are primarily based on a fixed fee or per member per month fee. Therefore, they do not require significant estimates and assumptions by management. See Note 6 Revenue Recognition.
Recent
accounting pronouncements
For more information on recently issued accounting pronouncements, see Note 2 to our Condensed Consolidated Financial Statements covered under Part I, Item 1of this Quarterly Report on Form 10-Q.
Emerging growth company status
We are an “emerging growth company” as defined in the JOBS Act of 2012. We will remain an emerging growth company until the earlier of (1) the last day of our fiscal year (a) following the fifth anniversary of the completion of our IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of
our common stock that is held by non-affiliates exceeds $700.0 million as of the last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained herein may be different than the information you receive from other public companies.
We
also take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our proxy statement and exemptions from the requirements of holding non-binding advisory votes on executive compensation and golden parachute payments.
Item 3. Quantitative and qualitative disclosures about market risks.
In the ordinary course of our business activities, we are exposed to market risks that are beyond our control and which may have an adverse effect on the value of our financial assets and liabilities, future cash flows and earnings. The market risks that we are exposed to primarily relate to changes in interest rates associated with our long-term debt obligations and cash and cash equivalents.
At March 31, 2022, we had total variable rate debt outstanding under our Credit Agreement of $348.3 million. If the effective interest rate of our variable rate debt outstanding as of March 31,
2022 were to increase by 100 basis points (1%), our annual interest expense would increase by approximately $3.5 million.
At March 31, 2022, our total unrestricted cash and cash equivalents were $451.3 million. Throughout the year, we invest any excess cash in short-term investments, primarily money market accounts, where returns effectively reflect current interest rates. As a result, market interest rate changes may impact our interest income. The impact will depend on variables such as the magnitude of rate changes and the level of excess cash balances. We do not consider this risk to be material. We manage such risk by continuing to evaluate the best investment rates available for short-term, high-quality investments.
Item
4. Controls and Procedures.
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
Our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial and Administrative Officer, to allow timely decisions regarding required disclosure.
In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on
Form 10-Q, an evaluation was carried out under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial and Administrative Officer of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial and Administrative Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial and Administrative Officer,
as appropriate to allow timely decisions regarding required disclosure.
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Due to the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures is also based partly on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control Over Financial Reporting
There have been no changes in the Company’s internal controls over financial reporting during the three months ended March
31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
From
time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. Although the results of litigation and claims are inherently unpredictable and uncertain, we are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, are believed to, either individually or taken together, have a material adverse effect on our business, financial condition or results of operations. Regardless of the outcome, litigation has the potential to have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
Item 1A. Risk Factors.
There
have been no material changes with respect to the risk factors disclosed in our 2021 Annual Report on Form 10-K.
Item 2. Unregistered Sales of Securities and Use of Proceeds.
The following financial information from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Changes in Members’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements
104*
Cover
Page Interactive Data File – The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 is formatted in iXBRL (included as Exhibit 101)
* Filed or furnished herewith
61
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
